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 INTRODUCTION 
 
Siddha system of medicine is one of the ancient traditional system of medicine. In 
Indian religion, “one who has attained perfection and bliss. The system is believed to 
be developed by the 18 siddhars of the south popular called this siddhars. 
Siddhars were spiritual adepts who possessed the ashtama siddhis, or the eight 
supernatural powers. 
Sage Agathiyar is considered the guru of the sidhars, Agathiyar is the first siddhar and 
his 18 disciples contributed thousands of texts on siddha, including medicine, and 
from the profounder of the system in this world. 
The basic theory of siddha system of medicine is “food is medicine - Medicine is 
food”. The human body is a composite of three humours such as vatham, pitham and 
kapam and seven physical mechanisms such as saaram (plasma), Senner (blood), oon 
(muscle), kozhuppu( fatty tissue). enbu (bone), Moolai (brain) and sukkilam or 
suronitham (Semon (or) Ovum). The food is considered to be fundamental building 
material of human body, which gets administered into humours, tissues and wastes. 
The siddha medicine recognizes predominance of vatham, pitham and kapam in 
childhood, adulthood and the old age respectively. 
Siddha medicine is claimed to revitalize and rejuvente dysfunctional organs that cause 
the disease and to maintain the ratio of vatham, pitaham and kapam. According to the 
siddha medince, various psychological and physiological functions of the body are 
attributed to the combination of seven elements. In siddha medicine also the 
Physiological components of the human beings are classified as vatham (air) pitham 
(fire) and kapam (earth and water).  
The eveness of humors, body tissues and waste products is studied as health and its 
imbalance leads to disease or pathologic state.  This system also deals with the 
thought to immortality and salvation in this life. The Exponents of this system belive 
that achievement of this state is possible by controlled diet, Medicine and possessing 
of mind by yogic or spiritual exercises like meditation and yoga. According  to siddha 
system, the human body, food and the drugs are the replica of the universe, 
 irrespective of their origin. Siddhars defined 96 principles as the constituents of 
human being. 
They comprise physical physiological, mental and intellectual machanisms of a 
person.  They are nothing but the mineralization neer, theyu, Vaayu, Aakayam these 
five elements (Bhoothams) are present in  every substance but in different proportions 
Earth , water, fire, air and  ether are manifestations of these five elements. 
When the normal equilibrium of the three humors (vadham, pitham and kapam) is 
disturbed disease is caused. The factors, which assumed to affects this equilibrium are 
environment climatic conditions, diet physical  activities  and stress. Under normal 
conditions the ratio between these humors, vatham, pitam and kapams is 4:2:1 
respectivley. According to the siddha medicine system, diet and lifestyle play a mojor 
role not only in health but also in curing diseases.  This concept of the siddha 
medicine is termed as pathyam and apathyam which is essentially a list of “do’s and 
don’ts”. 
In diagnosis examination of eight items is required which is commonly known as 
Envagai Thervugal. These are Naa ( tongue) Niram (Color ) Mozhi ( voice) Vizhi 
(eyes) sparisam ( touch ) Malam ( stool) Moothiram ( urine ) and Naadi ( pulse)  
The drugs used by the Siddhars could be classified into three groups: Thavara  
(Herbal products) Dhathu (inorganic substances) and sangaman (animal products) the 
drugs used in Siddha medicine are also classified on the basis of five suvai  
(Taste) gunam (character) veeriyam (Potency) pirivu (class) and a disciplined regimen 
of life are advised for a healthy living and to  restore equilibrium of humors in 
diseased condition. 
Neer Peenisam is very common disease in the society due to increasing exposure to 
air Pollution now a day. It is taken up for the authors dissertation study. 
In modern system of medicine, Neer peenisam is called sinusitis in children  
 
 
 The trai drug kandupaarangi chooranam (internal) Akirakattai Thailam  
(External) are choosen on the basis of classical attributes of respective ingredients  
according to the  specific action which may correct the vitiated humours in Neer 
peenisam. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIM AND OBJECTIVES 
AIM: 
 The author’s main aim is to collect and  review to ideas  mentioned 
Neerpeenisam in  ancient siddha literatures  about disease and also to know the efficacy 
of the trail drugs Kandupaarangi chooranam ( Internal ) and Akirkattai Thailam 
(External) as internal and External medince from Gunapadam Mooligai Vaguppu 
respectively in treating this disease. 
 The signs and symptoms mentioned in the disease drug Neer Peenisam can be 
compared to the sinusitis in children in modern. 
PRIMARY OBJECTIVE: 
 An Observational clinical study  on an open clinical trial   for  the disease 
Neerpeenisam using the  Siddha drug  Kandupaarangi chooranam (  Internal ) and  
Akirkattai Thailam ( External)  
SECONDARY OBJECTIVE: 
 To Collect authentic literature and review the siddha literature about the disease. 
 To evaluate the disease Neerpeenisam clinically by careful examination of Aetiology 
clinical features Treatment and prognosis 
 To describe the unique diagnostic procedure siddha literature for the disease Neer 
Peenisam 
 To have the clinical trial in Neerpeensiam, Kandupaaragi Chooranam (Internal) 
and Akirkattai Thailam (External)  
 To Evaluate to Biochemical Pharmacological analysis and antimicrobial activity of 
the trail medicine. 
 To study the extent of correlation of Neer peenisam explained in siddha literature  
with sinusitis in children  in modern literatures  
 To make use of modern parameters in the investigation to confirm the diagnosis and 
prognosis of the patient. 
 To educate the patients and their parents in terms of prevention of disease diet, habits  
and hygienic environment. To flourish the siddha system of medicine. 
 SIDDHA ASPECT 
ePh;gPdprk; 
NtWngah;: %f;filg;G Neha;> ePh;f;Nfhit> %f;F ePh; gha;jy; 
,ay;: 
 %f;fpd; Jisf;Fs; rpte;J fhzy;> Jk;ky;> fz;rpte;J ePh;tbjy;> 
%f;fpy; ePh; gha;jy;> jiyNehjy;> mbf;fb %f;if rpe;jp rsp> rPo;> FUjp 
ntspahjy; Mfpa ,ay;Gila NehahFk;. 
    -Neha; ehly; Neha; Kjy; ehly; jpul;L-2 
(g.vz;.83) 
 rpurpy; fdnyOe;J #iyahy; Nuhfk; mjpfhpj;J rPo; NghYk; 
rpuha;NghYk; fhzg;gLk; xU tpj %f;F tpahjp. 
    -T.V. rhk;g rptk; gps;is mfuhjp. (g.vz;.476) 
nghJFzk;: 
  “ghug;gh %yj;jpy; fdNy kpQ;rp 
   gf;Ftkha; fghyj;jpy; ePiuf; Nfhh;j;J 
   ePug;gh ehrp topNahLk; Jk;Kk; 
   epd;wilf;Fk; jiyfdf;Fk; gplhpNehtha; 
   Nrug;gh jpuz;LtpOk; ehWk; ehtpy;   
   Urpaw;W ehrpapdpy; kzK kw;W 
   tPug;gh ntJg;Gz;lhap rpu ePh; fPNo 
    tPw;wpwq;fp fgk; nfl;Lk; neQ;rpy; jhNd”. 
     - gpj;j gPdpr njhFjp A.T.S.V.SKQ;rpiw. 
 
 
 
 nghUs;: 
%yj;jpy; mdy; kpFe;J fghyj;jpy; ePh; Nfhh;f;Fk; 
ehrpapy; ePh; tbjy; 
Jk;ky; 
%f;filj;J jiy fdf;Fk; 
gplhp NehFk; 
ehw;wk; cz;lhFk; 
Ritapd;ik 
ehrpapy; kzk; mwpahJ 
rpurpy; ,Ue;J ePh; fPNo ,wq;fp neQ;rpy; fgk; fl;Lk;. 
Neha; tUk; top: 
gPdpr epjhdk; 
“je;ij jha; Fzj;jpdhYk; jd;Dl ghtj;jhYk; 
 jha; je;ij Kd;nra;j fh;kj;jhYk; #iyahYk;  
 nge;jkha; gPdprk; jhd; ngUj;jNjhh; rpfg;gpdhYk; 
 kdkjhf te;J kUtp tpLk; fpue;jp jhNd” 
 
“jhndd;w fpue;jp Neha;fs; je;jpLk; rpurpy; Kd;Nd 
 Cndd;w gPdprk; jhd; cw;wpLk; rpurpy; gpd;Nd 
 ghNdd;w gPdprj;jpy; gw;wpa Nuhfk; nrhy;y 
 jhndd;w cikahSf;fPrd; etpd;wNjhh; EhypjhNa” 
     - kjiy Neha; njhFjp -I g.vz; - 370 
 
 
 nghUs;: 
ngw;Nwhh;fspd; Fzj;jpdhYk; 
ngw;Nwhh; Kd; nra;j fh;k tpidahYk; 
#iyahYk; rpfg;gpdhYk; 
Kjypaf; fhuzq;fshy; Foe;ijfSf;F jiyapy; fpue;jp Njhd;Wk;. 
fpue;jpia njhlh;e;J gPdpr Neha; cz;lhtjhf gPdpr epjhdk; Ehy; 
$WfpwJ. 
kpf;f Fsph;e;j ePiug; gUFjy; gdp my;yJ Fsph;e;j fhw;wpyPLgly;. 
jdf; nfht;thg;Gif> GOjp $ba fhw;W Jk;kiy Az;lhf;ff;$ba 
nghUs;fshd ,tw;iw Kfh;jy;. cly; ntg;gile;Js;s NghJ rNunyd 
Iaj;ijg; ngUf;ff; $bajhd Fsph;e;j ePhpy; jiy KOfy;. Fsph;r;rp jUk; 
nghUs;fis cl;nfhs;sy; Mfpatw;whYk; ,e;Neha; gpwf;Fk;. md;wpAk; 
Nkf Neha;f;Fj; Jizaha; ,e;Neha; tUtJz;L. 
rpj;j kUj;Jthq;f RUf;fk; 
tpopePh:; 
 “tpopapdpy; ePulf;fpy; 
  tpjkhd ,Uj;Nuhfk; 
  topaL gPdprq;fs; 
  te;jpLk; Nej;ju Nuhfk; 
  mOfpLk; rpurpy; Nuhfk;” 
      - g.vz; - 211 
 
 
 
 
 Jk;ky;: 
 “Jk;kiyj; jiljhd; nra;jhy; 
 njhFj;jpLk; jiyNehAz;lhk; 
 ,k;ik ape;jphpa nky;yhk;  
 ,ay;Gld; njwpj;j yhFk; 
 nrk;ikapy; Kfk; typj;jy;”. 
      - g.vz; - 196 
epj;jpiu: 
 “epj;jpiu alq;fpg; Nghf 
  epfo;e;jpLk; fUkq; Nfsha; 
  epj;jKk; jiyf; fdg;G 
  epd;w fz;Nzha jhfp 
  rpj;jj;jpw; nrtpLz;lhfpf; 
  njsptW Ngr;R Kz;lhk;”. 
  Jk;ky;> epj;jpiu> fz;zPiu mlf;Ftjdhy; %f;filg;G Neha; 
cz;lhFk;. 
       -g. vz; - 208 
%f;filg;G ,Uky;:- 
 “nra;aNt ,UkNyhL Nfhio tPOk; 
  Nrl;kkh apidg;NghL ,iug;Gz;lhFk; 
  cg;gkha; tapwJT %jpf; nfhs;Sk; 
  CZwf;f kpy;yhk YyUe; Njfk; 
  Fg;gkha; kyryKq; fWfp tPOk; 
  Nfhioapl Fze;jhd; kPd; ftpr;r bf;Fk; 
  Jg;gkha; RUz;LtapW typAkhFk; 
  Rthr gPir nkd;Nw #l;blhNa”. 
- rpj;.k - 222 gps;isg; gpzp kUj;Jtk; g.vz; - 143 
 nghUs;: 
 ,UkNyhL Nfhio tpOk;. 
 rpNyl;k ,isg;NghL ,iug;G cz;lhFk;. 
 tapW cg;gp Cjpf; nfhs;Sk;. 
 grp> cwf;fk; ,y;yhky; ,Uf;Fk; 
 kyryk; fWfp tpLk;. 
 Nfhioapy; kPd; ftpr;r ehw;wkpUf;Fk; 
 tapWtyp cz;lhFk; 
 ,tw;iw Rthr gPdprk; vd;W ,e;Ehy; $WfpwJ. 
Kw;FwpFzq;fs;: 
 %f;fpy; xUtif vhpr;rYk; eikr;rYk; cz;lhfp mjidj; jhq;f 
KbahJ %f;Fj;Jisia Nja;j;J rptf;fr; nra;Ak;. 
 gpd; fz; rpte;J ePh; tbAk; 
 %f;F milj;jhw; Nghy; Ngrr; nra;J fhjilg;G> fhjpy; eikr;ry; 
cz;lhFk;. 
 jiy Neha;> %r;R cs;thq;fTk;> ntsptplTk; Kbahik vd;Dk; 
FwpFzq;fisAk; fhl;b %f;fpypUe;J jhdwpahkNyNa gdpePh; Nghy; 
nfhl;Lk;. 
Mj;kul;rhkph;jk;: 
 %yj;jpy; fdNywp fghyj;jpy; ePiuNaw;wp xU eh;rpiaailj;J xU 
ehrpapy; ePh; tbAk;. 
 mbf;fb Jk;ky; tpOjy; 
 gplhpAk;> jiyAk; fdj;J typf;Fk; 
 Njfj;jpy; ntJg;G 
 ehtpy; Ritapd;ik 
 kzKk; nfLk; 
 [Ptul;rhkph;jk;: (ehrpNuhf Ngjk;) 
 mjpf Jk;ky; 
 ehrpapy; NgRtJ Nghy; NgRjy; 
 %f;fpy; Jh;f;fe;jk; tPRjy; 
 jiyNehT ,itfSk; cz;lhFk;. 
Nehapd; tifg;ghl;bay;:- 
gPdpr tiffs;:- 
 Neha; ehly; Neha; Kjy; ehly; jpul;L - 09 
 T.V. rhk;grptk; gps;is mfuhjp   - 07 
 Mj;k ,ul;rhkph;j rhurq;fpufk;   - 09 
 [Ptul;rhkph;jk;      - 18 
 kjiyNeha; njhFjp     - 03 
 rpj;jh; mWit kUj;Jtk;    - 04 
Neha; ehly; Neha; Kjy; ehly; jpul;L 
9 tiffs; 
 tsp gPdprk; 
 moy; gPdprk; 
 Ia gPdprk; 
 ePh; gPdprk; 
 FUjp gPdprk; 
 rPo; gPdprk; 
 rpuha; gPdprk; 
 Kis gPdprk; 
 fz;l gPdprk; 
 T.V rhk;grptk; gps;is 
7 tiffs; 
 thj gPdprk; 
 gpj;j gPdprk; 
 rpNyl;Lk; gPdprk; 
 ePh; gPdprk; 
 rPo; gPdprk; 
 ,uj;j gPdprk; 
 rpuha; gPdprk; 
Mj;kul;rhkph;j rhurq;fpufk; vd;wE}y; $WtjhtJ 
 ‘fhg;ghd thjgPdpre; jhdhFk; 
  fUjpaNjhh; gpj;j gPdprK khFk; 
  thg;ghd rpNyj;k gPdprKkhFk; 
  tFj;j ePh;g;gPdprkhk; rPg;gPdprk; 
  Nrg;gh;d Tjpu gPdprKkhFk; 
  nropg;ghd rpwhg;gPdpr %yg;gPdprkhk; 
  Mg;ghd fz;l gPdp]e;jhdhFk; 
  mg;gNe xd;gJ tpj jpz;zkhNk”. 
9 tiffs; 
 thjg;gPdprk; 
 gpj;jgPdprk; 
 fgg;gPdprk; 
 ePh;g;gPdprk; 
 ,uj;jg;gPdprk; 
  rPo;g;gPdprk; 
 rpuha;g;gPdprk; 
 %yg;gPdprk; 
 fz;lg;gPdprk; 
 
[Ptul;rhkph;jk; 
 18 tiffs ; 
 thjgPdpr Nuhfk; 
 gpj;j gPdpr Nuhfk; 
 rpNyj;k gPdpr Nuhfk; 
 jphpNjh\ gPdpr Nuhfk; 
 ,uj;j gPdpr Nuhfk; 
 J\;l gPdpr Nuhfk; 
 ehrpfhNrh\ gPdpr Nuhfk; 
 ehrpfh ehf gPdpr Nuhfk; 
 fpudNkf gPdpr Nuhfk; 
 ehrpfhrput gPdpr Nuhfk; 
 mgPdpr rput gPdpr Nuhfk; 
 G+jp ehrpfh gPdpr Nuhfk; 
 Gf;rpu ehrpfh gPdpr Nuhfk; 
 ehrpfh Jk;gpf;if gPdpr Nuhfk; 
 ehrpfh G+jf gPdpr Nuhfk; 
 ehrpNuhf gPdpr Nuhfk; 
 ehrpfh mw;Gj gPdpr Nuhfk; 
 
 kjiyNeha; njhFjp I 
 “fhg;ghd nuj;jnkhd;W fz;bLk; #iynahd;W 
  Neh;g;ghd ryTnkhd;W eph;za kwpa Ntz;b 
  Ch;g;ghd Ngh;fs; %d;W cw;wpLk; rhj;jpak; mrhj;jpak; 
  Nrh;g;ghd rhj;jpuj;ij jhuzpapy; rhw;wf;NfNs”. 
  
3 tiffs ; 
 ,uj;j gPdprk; 
 RugPdprk; 
 #iygPdprk; 
rpj;jh; mWit kUj;Jtk; 
 4 tiffs ; 
 ePh; gPdprk; 
 FUjp gPdprk; 
 rPo; gPdprk; 
 rpuha; gPdprk; 
 
ePh;gpdpr FwpFzq;fs; 
 Fsph; fhw;wpyPLgly; 
 Fsph;e;j ePhpy; jiy KOfy; 
 kpf Fsph;r;rpahd ePh; tif my;yJ czTfisf; nfhs;sy; 
 jdf;nfht;th kz%l;Lk; nghUl;fNsDk; Jk;G J}rpfNsDk; 
%f;fpy; EioAk; gbahf Neh;jy; 
 clNd %f;filj;Jj; jdf;Fj; njhpahkNy %f;fpdpd;W ePiur; 
nrhl;lr; nra;Ak;. 
  ,jdpy; tbAk; ePh; kpfj; njspthfTk; fhzg;gLk; 
 jiyNeha; rpW Ruk;> cly; Nrhk;gy;> if fhy; Nehjy; Mfpait 
cz;lhFk;. 
 ehrpePh; tbe;J kio fhyj;jpy; Jk;ky;> fOj;J typ> gplhpAk; KfKk; 
Cjy; Mfpait cz;lhFk;. 
Kf;Fw;w NtWghLfs;:- 
 czT Kjypa nray;fshy; cly; ntg;gkile;J moy; Kw;Wk; 
kpFe;jNghJ Iaj;ijg; ngUf;ff;$ba nray;fshy; gpwe;j Iak; 
moNyhL $bg; gpwe;j NehahFk;. 
 md;wpAk;> xf;f epiyapy; fPo;tha;f;fdy; kpf ngUfpDk;. 
 Nky; Nehf;Fq;fhypd; td;ikahy; kz;iltiuapy; gha;r;rYs;s 
epiyapy; Iaq; $bDk; ,e;Neha; gpwf;FnkdTk; rpy E}y; $Wk;. 
gpzpawp Kiwik:- 
 gpzpawp Kiwik vd;gJ cliyg; gpzpj;jyha Nehiaj; njhpe;J 
nfhs;Sfpw xOf;fk;. 
,J :- 
nghwpahywpjy; 
Gydhywpjy; 
tpdhjy; 
nghwp:- 
nka; 
tha; 
fz; 
%f;F 
nrtp 
 kUj;Jtd; jd; nghwpfshy; Nehahspfsplk; nghwpfis mwpjy;. 
 Gyd;:- 
ehw;wk; 
Rit 
xsp 
CW 
Xir 
tpdhjy;:- 
 Nehahspapd; FLk;g tuyhW> taJ> cly;td;ik> kd cWjp> gz;G 
nrhpg;Gjd;ik> ,aw;if> czT> thOkplk;> mt;tplj;jpd; jd;ik> Nehapd; 
taJ Neha; Njhd;wpa fhyk;> ,lk;> Neha; cz;lhtjw;F Kd;G Nehahspapd; 
epiyik Mfpatw;iw Nfl;Lj; njhpe;J nfhs;Sjy;. 
vz;tifj; Njh;Tfshtd:- 
 ‘ehb ];ghprk; ehepwk; nkhoptpop 
  kyk; %j;jpu kpit kUj;JtuhAjk;”. 
     - Neha;ehly; Neha; Kjy; ehly; - 253 
ehb:- 
 Njfj;jpdplj;NjAs;s vy;yhcWg;GfspYk; rpwe;jJ ,Ujak;. ,jd; 
%ykhfj;jhd;. jhJf;fs; ahTk; Ngh\pf;fg;gLfpd;wd. ,JNt Njfk; 
ed;dpiyapypUg;gjw;Fk; Rfkpy;yhikf;Fk; fhuzk;. ,jd;njhopy; 
NtWghLfis ehbfs; czh;j;Jk;. 
ehb eil rhpahfj; Njhd;whj epiyfs;:- 
 “nfhz;blNt faNuhfp fhrNuhfp 
  FwpNghff; rpw;wpd;gk; nra;j Ngh;fs; 
 mz;blNt jhpj;jpuh;fs; tpUj;jh; ghyh; 
  md;ghfj; jz;zPhpy; %o;fpNdhh;fs; 
 nfhz;blNt ,th;fsJ cWg;gpd; jhJ 
  $wNt KbahJ vth;f;Ff; fpl;Lk; 
 gz;blNt apg;ghPl;ir ahh;jhd; fhz;ghh; 
  guhguj;jpd; kpfpikapJ ghUghNu” 
     (Neha; ehly; Neha; Kjy; ehly; - 162) 
 ePh;epwf;Fwp:- 
 ‘mUe;J khwpujKk; mtpNuhjkjha; 
  m/fy; myh;jy; mfhyT+d; jtph;e;jow; 
  Fw;wstUe;jp cwq;fp itfiw  
  Mbf;fyrj; jhtpNa fhJ nga; 
  njhUK$h;j;jf; fiyf;Fl;gL ePhpd; 
  epwf;Fwp nea;f;Fwp epUkpj;jy; flNd” 
    - Neha; ehly; Neha; Kjy; ehly; (g.vz;.-282) 
nea;f;Fwp: 
 Foe;ijfspd; ehb eil rhpahf fdpg;gjpy; rpukk; cs;sjhy; 
nea;f;Fwp ghpNrhjid %yk; Nehahsh; vf;Fw;wj;jhy; ghjpf;fg;gl;Ls;sd 
vd;gjid ftdpf;fyhk;. 
 “epwf;Fwpf; Fiue;j jpUkhz ePhpw; 
  rpwf;f ntz;nza;Nahh; rpWJsp eLtpLj; 
  njd;wj;jpwe;njhtpNahf jikj;jp 
  dpd;wjptiy Nghk; newptpopg;gwpTk; 
  nrd;wJ GfYQ; nra;jpia GzNu” 
   - Neha; ehly; Neha; Kjy; ehly;. (Kjy; ghfk;-279) 
 vd;gjhy;> Nehiar; fz;Lgpbj;jw; nghUl;L nrhy;ypapUf;fpd;w tpjp 
nghUe;jpa rpWePhpy; vz;nza; xU Jsp rpjwhky; tpl;L nta;ypyhtJ. 
me;ePhpy; gLk;gb jpwe;j fhw;whdJ mjpy; tPjp me;j vz;nza;j; Jsp 
Mlhjgb itj;J> rpWePhpy; tplg;gl;bUf;fpd;w vz;nza;j; JspahdJ 
nrhy;Yfpd;w topahy; Nehia mwpe;J nfhs;syhk;. 
  
 
  ‘muntz ePz;bbd/Nj thjk;” 
 ‘Mop Nghw;gutpd; m/Nj gpj;jk;” 
 ‘Kj;njhj;J epw;fpd; nkhoptnjd;fgNk” 
  -Neha; ehly; Neha; Kjy; ehly; Kjy; ghfk; gf;.vz;.279 
Kf;Fw;wk;:- 
 jrehbfs; gj;jpy; %yhjhukhf epd;wJ ,l fiy> gpq;fiy> 
RopKid vd %d;W ehbfshFk;. ,e;j %yhjhu ehbfis KiwNa 
mghdd;> gpuhzd;> rkhdd; vd;Dk; thQf;fspd; ,af;fj;jhy; tpLk; 
Rthrk; vdyhk;. 
,lfiy + mghdd; = thjk; - 1 khj;jpiu 
gpq;fiy + gpuhzd; = gpj;jk; - ½ khj;jpiu 
RopKid+ rkhdd; = Iak; - ¼ khj;jpiu 
thjk;:- 
 tsp xd;whapUg;gpDk; jk; ,lk;> njhopy; Kjypatw;why; gj;J 
tifg;gLk;. 
 
thpir 
vz; thjk; ,Ug;gplk; njhopy; 
1. gpuhzd; 
jkufj;jpdpd;W 
%f;F tiu 
kdk;> Gj;jp> cs;sk;> Ik;nghwp 
,itfisj; jd;dpiyg;gLj;jp> 
fhwpAkpo;jy;> ,Uky;> Jk;ky;> 
Vg;gk; tply;> %r;Rtply; thq;fy; 
cz;Zk; czit 
cl;nrYj;jy; Mfpait. 
 
2. mahdd; 
vUthapypd;W 
mbtapW 
ntz;zPh;> ehjk;> kyk;> rpWePh;> 
fU ,tw;iw ntspg;gLj;Jk;. 
 ,Ug;gpd; G+l;L> 
ePh;g;ig Mz; 
ngz; Fwpfs;> 
njhil. 
3. 
rkhdd; 
gf;Fthrak; 
(tapW) 
gf;Fthrak; 
(tapW) 
rhuj;ijAk;> jpg;gpiaAk; 
ntt;Ntwhf gphpj;J> rhuj;ij 
clypd;  vy;yh ghfq;fSf;Fk; 
gfph;e;J nfhLf;Fk;. 
4. tpahdd; jkufk; 
elj;jy;> cly; cWg;Gfis 
mirj;jy;> fz; ,ikj;jy; 
tpopj;jy;. 
5. cjhdd; khh;G 
Ngr;Rf;F Kjw;fhuzkha; 
,Ue;J> Kaw;rp> kdjpy; 
cly;td;ik< cly;epwk;> 
cly;xsp> epidT Mfpait. 
6. ehfd; fz; 
fz;fisj; jpwf;fTk; 
,ikf;fTk; nra;Ak; kaph;fis 
rpyph;f;fr; nra;Ak;. 
7. $h;kd; 
kdjpypUe;J 
fz; tiu 
,ikia nfhl;Ltpf;Fk;> 
nfhl;lhtp tplg;gz;Zk; thia 
%lg; gz;Zk;. 
8. fpUfud; ehf;F 
ehtpw; frpitAk;> ehrpapw; 
frpitAk; cz;lhf;Fk;> kpFe;j 
grpiaAz;lhfr; nra;Ak;> 
xd;iw epidj;jpUf;f 
cz;lhf;Fk;. 
9. 
Njtjj;jd; Fjk;> Fa;ak; Nrhk;gy;> cly; Khpj;jy; 
cz;lhf;Fk; jhq;Fjy;> rz;il 
nfhs;sy;> jhf;fk; Ngry;> 
kpFe;j Nfhgk; cz;lhf;Fk;. 
 10. 
jdQ;nrad; %f;F ,we;jhy; fhw;W ntspg;gl;l 
gpd;G %d;W ehspy; jiy 
ntbj;Jg; NghFk;. 
  
 ePh; gPdprj;jpy; gpuhzd;> tpahdd;> cjhdd;> rkhdd;> ehfd;> 
$h;kd;> fpUf;fud; ghjpg;gilAk;. 
 gpuhzd; : %r;Rtpl rpukk;> Jk;ky;> ,Uky; 
 tpahdd; : jiytyp> jiyghuk; 
 cjhdd; : Jk;ky; 
 ehfd; : fz;fspy; typ 
 $h;kd; : fz;zpy; ePh;tbjy; 
 fpUfud; : Jk;ky;> %f;fpy; ePh; tbjy; 
 
gpj;jk;:- 
 
thpir 
vz; 
gpj;jk; ,Ug;gplk; njhopy; 
1. 
mdw;gpj;jk; ,iug;igf;Fk; 
gf;Fthraj;jpw;F 
,ilapy; 
ePh; tbt Ks;s nghUs;fis 
twsr; nra;J> cz;l czTg; 
nghUs;fis nrhpf;f gz;Zk;. 
2. 
,uQ;rfk; ,iuf;Fly; cztpypUe;J gphpe;Jz;lhd 
rhw;Wf;F nre;epwj;ij 
jUfpwJ. 
 
3. 
rhjfk; jkufk; kdk;> Gj;jp> gw;W ,tw;iwf; 
nfhz;L tpUg;gkhd njhopiy 
nra;Ak;. 
 4. 
MNyhrfk; fz; vy;yhg; nghUs;fspd; 
tbtj;ijAk; mwpjyhfpa 
fhhpaj;ijr; nra;Ak; 
5. 
gpuhrfk; Njhy; NjhYf;F xspiaf; 
nfhLf;Fk;. 
ePh;gPdprj;jpy;> rhjfk;> MNyhrfk; ghjpg;gilAk;. 
 rhjfk; : jd; md;whl Ntiyia nra;a rpukk; 
 MNyhrfk; : fz;zpy; ePh; tbjy;> fz;zpy; typ 
Iak;:- 
thpir 
vz; 
Iak; ,Ug;gplk; njhopy; 
1. mtyk;gfk; EiuaPuy; kw;w ehd;F Iaq;fSf;Fk; 
gw;Wf; NfhlhapUf;Fk;. 
2. fpNyjfk; ,iug;ig 
cz;zg;gl;l czTg; 
nghUl;fs; ePh; Kjypaitfis 
<ug;gLj;jp nkj;njd nra;Ak;. 
3. Nghjfk; ehf;F 
cztpd; Ritia 
mwpaitf;Fk;. 
4. jw;gfk; jiy fz;Zf;F Fwph;r;rp jUk;. 
5. re;jpfk; fPy;fs; 
fPy;fis xd;Nwhnlhd;W 
nghUj;jpj; jsur; nra;Ak;. 
ePh; gPdprj;jpy; mtyk;gfk;> jw;gfk; ghjpg;gilAk;. 
 mtyk;gfk; : ,Uky; 
 jw;gfk; : fz;zpy; ePh;tbjy;> fz; vhpr;ry;. 
gUtfhyq;fs;:- 
 G+kp Qhapw;iwr; Rw;wp tUtjw;F Xh; Mz;L Mfpd;wJ. ,J ngUk; 
nghOjhk;. ,J MW gFjpfisg; ngw;Ws;sJ mit. 
 fhh;fhyk;  - Mtzp> Gul;lhrp (August, September) 
  $jph;fhyk;  - Ig;grp> fhh;j;jpif (October, November) 
 Kd;gdp fhyk;  - khh;fop> ij (December, January) 
 gpd;gdp fhyk;  - khrp> gq;Fdp (February, March) 
 ,sNtdpw; fhyk;  -  rpj;jpiu> itfhrp ( April, May) 
 KJNtdpw;fhyk;  -  Mdp> Mb (June, July) 
epyk;:- 
 kf;fspd; jd;ik mth;fs; trpf;Fk; epyj;ij nghUj;Nj mikAk;. 
ahtw;wpw;Fk; epyNk Mjhukhf ,Uf;fpwJ. 
epyk; Ie;J tifg;gLk; mit 
 FwpQ;rp -  kiyAk;> kiy rhh;e;j ,lKk; 
 Ky;iy -  fhLk;>fhL rhh;e;j ,lKk; 
 kUjk; -  taYk;> tay; rhh;e;j ,lKk; 
 nea;jy; -  flYk;>fly; rhhe;j ,lKk; 
 ghiy  -  kzYk; kzy; rhhe;j ,lKk; 
 
clw;jhJf;fs; 
VO tifg;gLk; mit. 
thpir 
vz; 
clw;jhJf;fs; njhopy; 
1 rhuk; cliyAk;> kdijAk; Cf;fKwr; nra;Ak; 
2 nre;ePh; 
mwpT> td;ik> xsp> nrUf;F xyp ,itfis 
epiyf;fr; nra;Ak; 
3 Cd; 
clypd; cUtj;ij mjd; njhopw;fpzq;f 
mikj;J vd;ig tsh;f;Fk; 
4 nfhOg;G fbdkpd;wp ,aq;f cjTk; 
 5 vd;G cliy xOq;Fgl epWj;jp  itf;fpwJ 
6 %is 
vd;Gf;Fs; epiwe;J  mitfSf;F td;ik 
kw;Wk; nkd;ik jUk; 
7 ntz;zPh; 
jd;id nahj;j cUtk; ngUf;fpw;F ,lkhfpa 
fUj;Njhw;wj;jpw;F Kjyha; epw;gJ 
 ePh;gPdpj;jpy;  rhuk;> nre;ePh;  ghjpg;gilAk; 
vz;tifj; Njh;Tfs;:- 
 vl;L NtWgl;l Nrhjidfis  Nehapd; ghy; Nkw;nfhz;L  
kUj;Jtd;  Nehapid fzpf;Fk; KiwikNa vz;tifj; Njh;Tfshk;.  
mitfis m\;ltpj ghpl;i\ vd tlnkhop Ehw;fs; gfUfpd;wd. 
mitahtd 
1. ehb 
2. ];ghprk; 
3. eh 
4. epwk; 
5. nkhop 
6. tpop 
7. kyk; 
8. %j;jpuk;  
1. ehb: 
 clypy; caph; jdpj;jpUg;gjw;F fhuzkhdnjJNth mJNt ehb 
my;yJ jhJ MFk;. 
 ,q;F Ma;tpw;F cl;gLj;jg;gl;l  Foe;ijfSf;F gpj;jthj ehb> 
fgthjehb> gpj;jfg ehb fhzg;gl;lJ. 
 
 
 (i) gpj;jthj ehb 
 “rpwg;ghd gpj;jj;jpy; thjehb 
   NrhpYWjhJehl;l KjugPil 
  ciwg;ghfr; nrhpahikf; fpd;kQ; #iy 
   cw;wRuq; fpuhzptapw; wpiur;ry; ke;jk; 
  miwg;ghd Xq;fhu GwePh;f; Nfhit 
   Mahr kpuf;fnkhL kaf;f %h;r;ir 
  Kiwf;fha;T tp\tPf;fk;  %y tha;T 
   Kulhd Neha;gyT KLFk; gz;Ng” 
       - (rjf ehb) 
-Neha; ehly; Neha;Kjy; ehly; jpul;L ghfk; - I> g.vz; - 184 
(ii) fgthjehb  
  “fz;lhNah rpNyw;gzj;jpy; thj ehb 
   fye;jpLfpy; tapW  nghUky; fdj;j tPf;fk; 
   cz;lhNah Xq;fuQ; rf;jp tpf;f;y; 
   cWjpul;ir tha;Ttyp re;jp Njhlk; 
   tpz;lhNy ,isg;gpUky; Nrhig ghz;L 
   tplghfk; tpl#iy gf;f thjk; 
   jpz;lhL ehrpfh  gPlq; ff;fy; 
   rpuNeha;fs; gyTk; te;J  rpf;Fe;jhNd 
         (rjfehb) 
-Neha; ehly; Neha;Kjy; ehly; jpul;L ghfk; - I> g.vz; - 186 
(III) gpj;jfgehb 
 “gz;ghd gpj;jj;jpy; Nrj;Jk ehb 
   ghprpj;jh yj;jpRu gpisg;G <id 
   fz;fhJ  eadkyk; ePU kQ;rs; 
   fdtapW nghUky; kQ;rs; Neha; fz;NehT 
  tzpNghJ kwj;jy; ,uj;j tpg;GUjp jhDk; 
   ciskhe;ij gPdrKk; ,uj;j tPf;fk; 
  ez;ghd fhkhiy Nrhif ntg;G 
   eZfpte;j gygpzpAk; ez;Ze; jhNd” 
         (rjf ehb) 
-Neha; ehly; Neha;Kjy; ehly; jpul;L ghfk; - I> g.vz; - 185 
2.];ghprk; 
 cly;#lhAk;> typ> tPf;fk; fhzg;gl;lJ 
3. eh 
 ehtpy; Ritawpahik 
4. epwk; 
 %f;fpd; Edprpte;J fhzg;gl;lJ 
 
5. nkhop 
 Kf;filj;J %f;fhy; NgRtJ Nghd;w xyp 
6. tpop 
 fz;rpte;J>vhpr;rYld; fhzg;gl;lJ. fz;zpy; ePh; tbe;J 
fhzg;gl;lJ 
7. kyk; 
 Fwpg;gpLk;gb ve;j khw;wKk; ,y;iy. 
8. %j;jpuk; 
 ,ay;ghf fhzg;gl;lJ 
 kUj;Jtk; 
 “Neha;ehb Neha; Kjy;ehb mJ jzpf;Fk; 
  tha;ehb tha;g;gr; nray;” 
 -jpUf;Fws;> kUe;J mjpfhuk; 
 “cw;whdsTk; gpzpasTk; fhyKk; 
  fw;whd; fUjpr; nray;” 
-jpUf;Fws;> kUe;J mjpfhuk; 
kUj;jt topKiw 
  Ia Fw;wj;ij jd;dpiygLj;jNtz;Lk;  
gj;jpak; 
  “gj;jpaj;jpdhNy gyDz;lhk; kUe;J  
  gj;jpaq;fs; Nghdhy; gyd; NghFk; gj;jpaj;jpy; 
   gj;jpaNk ntw;wpjUk; gz;bjh;f;F Mjypdhy; 
  gj;jpaNk cj;jp nad;W ghh;” 
     -(Njiuah;)  
 
 kUe;Jz;Zk; fhyq;fspy;  Nehahspapd; Nehapd; jd;ik nghUj;J 
czT kw;Wk; nray;fspy; MFk;. Mfh gj;jpaq;fs;mwpTUj;jg;gLfpwJ.  
czT 
MFk; gj;jpak; 
 “gj;jpaq; Nfhop Kl;il gRk;ghy; Kj;jnea; KUq;ifapiy 
  kw;Wk; epfhpy; fj;jhpf; $l;Lk; gj;JNkJitu jhDk; 
   gz;ghd gPdprk; NghNk” 
         -Fzghlk; 
nghUs;: 
  NfhopKl;il> gRk;ghy;> Mkzf;F nea;> KUq;ifapiy> 
fj;jphpf;$l;L> Jtiu cl;nfhs;s gPdprk; ePq;Fk; 
 cztpy; clw;F ntg;gj;ijj; jUk; nghUfshfNt nfhs;Sjy; 
Ntz;Lk;. 
 kpsF Nrhe;j ,urk;> Fok;G tif nfhs;Sjy;  
 fhprhiy kzj;f;fhsp fj;jphpg;gpQ;R Nghd;w fha;fwpfis 
nfhs;Sjy; 
Mfhgj;jpak;:- 
 Riuf;fha;> G+rzpf;fha;> gPh;f;F> Gliy  Kjypa Iaj;jijg; 
ngUf;ff;$baitifis ePf;fp itg;gJ kpf ed;whk;. 
Neha; jLg;G Kiw khw;wk; kUj;Jt mwpTiu 
 Nehahsp jdf;F xt;thj nghUl;fis fz;lwpe;J mjid ePf;f 
Ntz;Lk; 
 Rfhjhukw;w czTtiffs; kw;Wk; ePhpid jtph;f;fTk; 
 Fsph;fhw;W> gdpfhw;wpy; ntspapy; nry;tij jtph;f;fTk; 
 cztpid ,sQ;#l;by;  cz;z Ntz;Lk; 
 ,utpy; czit rPf;fpuk; cz;L rpwpJ Neuk; nrd;w gpd;G 
cwq;f nry;y Ntz;Lk;. 
 Neha; vjph;g;G rf;jpia jUk; rj;Js;s czTfis cz;z 
Ntz;Lk;. 
 Ghpe;J nfhs;Sk; tajpYs;s Foe;ijfSf;F gpuzhahkk; 
Nghd;w vspa %r;Rgapw;rp Kiwfis fw;WjUjy; Ntz;Lk; 
 fgNeha;  cs;sth;fs;  rpw;wPr;rghapy; cwq;fyhk; vd;W 
$wg;gl;Ls;sd.  
 MODERN ASPECT 
ANATOMY OF SINUS: 
Sinus is a sac cavity in any organ  or tissue, or an abnormal cavity or passage 
caused by the destruction of tissue.  In common usage, “Sinus” usually refer’s  to the 
paranasal sinuses, which are air cavities in the cranial bones, especially those near the 
nose and connecting to it.  Most individuals have four paired cavities located in the 
cranial bone or skull. 
Sinus is latin for “bay”, “pocket”, “curve”, or “bosom”.  In anatomy, the term is 
used in various contexts. 
The word “Sinusitis” is used to indicate that one or more of the membrane linings 
found in the sinus cavities has become inflamed or infected. 
It is however distinct from a fistula, which is a tract connecting two Epithelial 
surfaces.  If left untreated infections occuring in the sinus cavities can affect the chest and 
lungs. 
 Paranasal sinuses 
 Maxillary 
 Ethmoid 
 Spenoid  
 Frontal 
 Subcapsular sinus 
 Medullary sinuses 
 Trabecular sinuses 
  Dural venous sinuses 
 Inferior sagittal 
 superior sagittal  
 Straight  
 Occipital 
 Confluence of sinuses 
 Cavernous  
 Inferior  petrosal 
 Transverse 
 Sigmoid  
 Carotid sinus 
 Renal sinus 
 Coronary sinus 
 
The Development of the sinuses 
Sin
us 
Gestational 
Month When 
Development  Starts 
Present In 
Clinically Significant 
Size 
Fully 
Developed 
Maxillary  2 Birth 12 years 
Ethmoid  3 Birth 12 years 
Frontal  4 3 years 18-20 years 
Sphenoid  3 8 years 12-15 years 
 
SINUSITIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 THE FOUR PAIRED SINUSES OR AIR CAVITIES CAN BE REFFERED 
TO AS : 
 Ethmoid sinus cavities which are located between the eyes. 
 Frontal sinus cavities which can be found above the Eyes (more in the 
forehead region). 
 Maxillary sinus cavities are located on either side of the nostrils (cheekbone 
areas). 
 The maxillary sinus is the largest paramasal sinus and lies inferior to the Eye 
in the maxillary bone.  It is the first sinus to develop and is filled with fluid at 
birth.  It grows according to a biphasic pattern, in which the first phase occurs 
during years 0-3 and the second during years 6-12. 
 The sphenoid sinuses that are located behind the eyes and lie in the deeper 
recesses of the skull. 
 The presence of sinus cavities with in the cranial bone (skull) is essential 
for the following  reasons : 
 Sinus cavities allow for voice resonance. 
 They help filter and add moisture to any air that is inhaled through the nasal 
passages on to of filtering and adding moisture to the air we inhale, they also 
help in the removal of unwanted particles from the sinus cavities. 
 Sinus cavities provide a means to lighten the overall weight of the skull.        
 
 
 
 
 
 
 SINUSITIS 
 Sinuses are moist air space within the bones of the face around the nose.  When 
they become infected and swellor become irritated this is called sinusitis. 
 Sinusitis is common illness of childhood and adolescence with significant acute 
and chronic morbidity as well as the potential for serious complications. 
 There are 2 types of Acute sinusitis, viral and bacterial.  The common cold 
produces a viral, self – limited Rhinosinusitis.  The frontal sinuses may become 
involved only after 5-6 years of life. 
 Risk factors associated with sinusitis include recurrent upper respiratory 
infections (URI). 
 Allergic rhinitis 
 Cystic fibrosis 
 Immunodeficiency 
 Ciliary dyskinesia  
 Day care attendance 
 
ETIOLOGY 
The sinuses are four sets of hollow spaces that are located in the cheekbones 
(maxillary sinus).  The forehead (frontal sinus), behind the nasal passages (ethmoid sinus) 
sinuses are lined with the same  membranes that line the nose and mouth.  
When some one has a cold or allergies and the nasal passages become swollen and 
make more mucous, so sinus tissues.  The drainage system for the sinuses can get 
blocked, and mucous can become trapped  in the sinuses.  Bacteria viruses and fungi can 
grow.  There and lead to sinusitis. 
The most common is dates in acute sinus infections are S.pneumoniae,  
M.Catarrhalis.  These same bacteria are implicated in chronic sinusitis, as are S.aureus, 
Anaerobes, H.influenzae, α and β haemolytic  streptococci, and coagulalse – negative 
staphylococci. 
 EPIDEMIOLOGY : 
Acute bacterial sinusitis can occur at any age.  Predisposing conditions include 
viral upper respiratory tract infection, allergic rhinitis. 
PATHOGENESIS : 
Acute bacterial sinusitis typically follows a viral upper respiratory tract infection 
initially, the viral infection produces a viral  Rhinosinusits.  Paranasal sinuses in 68% of 
healthy children in the normal  of the common cold.  Nose blowing has been 
demonstrated to generate sufficient force to propel  secretions in to the sinus cavities.  
Bacteria from the nasopharynx that enter the sinuses are normally dead readily, but during 
viral Rhinosinusitis inflammation and oedema may block sinus drainage and impair.  
Mucociliary clearance of bacteria.  The growth conditions are favorable and high titers of 
bacteria are produced. 
CLINICAL MANIFESTATIONS :  
Children and adolescents with sinusitis may present with non specific complaints, 
including nasal congestion, prulent nasal discharge, fever and cough less common 
symptoms include bad breath, a decreased sense of smell, and periorbital odema 
complaints of headache and facial pain are rare in children. 
(i) Sinusits can cause different symptoms for kids of varing ages. 
Younger kids often have cold – like symptoms, including a stuffy or runny nose 
and slight fever.  If your child develops a fever 5-7 days after cold symptoms begin it 
could signal sinusitis or another infection. 
DIAGNOSIS 
  INTERROGATION 
 The time of onset of symptoms  
 Periodicity (variable during the day or seasonal) 
 Severity 
 Excerbating or relieving factors and other associated symptoms should be 
asked. 
  A full medication history as well as all the medicines used in the the past is 
important. 
 Any family history including atopy, past medical and surgical history and 
environmental conditions should be sought. 
EXAMINATION  
Examination of the PNS may be done as follows. 
 Examination of nose and face  
 Sinus tenderness 
 Examination of both ear, pharynx, larynx and neck. 
INSPECTION AND PALPATION: 
 This is done to defect any deformity, asymmetry or swelling of the nose and 
face. 
 Depression or deviation of the nasal bridge due to injury or disease may be 
present. 
 Gentle palpations of nose work may defect crepitus fractured nasal bones. 
 The nose is examind in a good light and any scars are noted (hidden scars) 
 The cosmetic “appropriateness” of the face is noted. 
 The ears, the mouth and throat must also be examined for evidence of 
involvement in any nasal condition. 
 Good illumination is necessory to inspect  the nasal cavities (ie) Ant, 
rhinoscopy. 
The first goal in diagnosing sinusitis  is to rule out other possible causes of 
symptoms, and then determine. 
 The site where the infection has occurred. 
 Whether the condition is acute or chronic. 
 The organism causing the infection (if possible). 
 
 IMAGING TECHNIQUES 
1.COMPUTER TOMOGRAPHY 
Computer tomography (CT) scanning is the best method for viewing the paranasal 
sinuses. 
2. X-RAY : 
Until the availability of endoscopy and CT scans, x-rays were commonly used.  
They are not as accurate, however, in identifying abnormalities  in the sinuses.  For 
example, more than one x-ray is needed for diagnosing frontal and sphenoid sinusitis.  x-
rays do not detect ethmoid sinusitis as accurately.  This area can be the primary site of an 
infection that has spread to the maxillary or frontal sinuses. 
3. PREVENTION: 
Prevention is best accomplished by frequent hand washing and avoiding persons 
with colds. 
Because acute bacterial sinusitis can complicate influenza infection, prevention of 
influenza infection by yearly influenza vaccine will prevent some cases of complicating 
sinusitis. 
Immunization or chemoprophylaxis against influenza with oseltamivir or 
zanamivir may be useful for prevention of colds caused by this pathogen and the 
associated complications,  influenza is responsible for only a small proportion of all 
colds. 
UPPER RESPIRATORY TRACT INFECTION : 
 Upper respiratory tract infections are those primarily affecting the 
structures of the respiratory tract above the larynx, but most respiratory illness affect both 
the upper and lower portions of the tract simultaneously of sequentially. 
 
 
  Inflammatory infiltrates. 
 Edema of the mucosa. 
 Vascular congestion. 
 Increased mucus secretion. 
ETIOLOGY : 
 Most acute respiratory tract infections are caused by viruses and mycoplasma 
 Strephococci and the diptheria organisms are the major bacterial  agents capable 
of causing primary pharyngeal disease 
ALLERGIC RHINITIS 
Allergic rhinitis is an inflammatory disorder characterized by sneezing,  itching, 
Nasal blockage , and clear rhinorrhea.  The symptoms may be seasonal (hay fever) or 
perennial the fluid from the nose is usually clear symptoms onset is often with in minutes 
following exposure and they can affect sleep, the ability to work, and the ability to 
concentrate at school.  Many people with allergic rhinitis also have asthma, allergic 
conjunctivitis (or) atopic dermatitis. 
IgE antibodies attaching to the allergen and causing the release of inflammatory 
chemicals such as histamine from mast cells. 
IMMUNODEFICIENCY : 
Children with immune deficiencies particularly of antibody production 
(Immunoglobulin G( IgG, IgG subclasses, IgA) 
TREATMENT :  
 Although a significant number of acute sinusitis episodes will resolve 
spontaneously most authors recommend antibiotics as the cornerstone of 
treatment. 
 As in acute otitis media, antibiotic should be the first line of medical therapy for 
acute sinusitis.  The exact duration of therapy is not clear, but most clinicians feel 
 that of symptoms have already persisted for 7-10 days, the infection should be 
treated for at least 14 days. 
 Longer courses and second line antibiotic agents are indicated for refactory 
infections, and parental antibiotics are the agents of choice for sinusitis with 
orbital or intracranial complications. 
 Other adjuvant measures that may have a possible benefit include oral 
decongestants, mucolytic agents, and topical nasal saline. 
 Topical decongestants may be used in sinusitis with complications.  Antihistamine 
are detrimental due to this drying effect on mucosal secretions and are best 
avoided. 
 Antibiotics are also the mainstay of treatment for chronic sinusitis.   
 The duration of treatment is longer than for acute sinusitis, typically  3 to 6 weeks. 
 Patients who have a true penicillin allergy may be treated with a macrolide 
antibiotic, although there is increasing resistance of sinus pathogens to these 
drugs. 
 Topical nasal steroids may also play a role in the treatment of chronic sinusitis. 
 Surgical intervention for acute sinusitis is limited to those with orbital or 
intracranial complications. 
 Surgery may also be considered for patients with chronic sinusitis who have not 
responded to aggressive medical management. 
 First line surgical therapy usually consists of adenoidectomy to remove the 
adenoid  pad as a bacterial reservoir for the sinuses. 
 Significant controversy exists regarding the indications for endoscopic sinus 
surgery (ESS) in pediatric patients. 
 Selected circumstances in which ESS may be of benefit include patients with 
sinonasal polyposis, cystic fibrosis, or those who symptoms have not responded to 
adenoidectomy. 
 
 
 MATERIALS AND METHODS 
The study of Neer peenisam was performed under the paper valuable guideline of 
the Headof the Department of Kuzhanthai Maughuvam department, siddha Medical 
College, Palayamkottai. 
The studies cases were carried out from P.G. Kuzhanthai Maruthuvam department 
both OPD and IPD in Government Siddha Medical College, Palayamkottai. 
SELECTION OF THE CASES: 
The cases were selected according to the symptoms and signs mentioned in the siddha 
text, certain criteria are followed for case selection. They are: 
INCLUSION CRITERIA: 
 Age – between 7 – 12 years.  
 Sex – Male and Female children. 
 Pain and tenderness around nose below orbit, and maxillary region.  
 Head ache associated with vomiting.  
 Fever due to sinusitis 
 Nasal congestion due to sinusitis. 
 HIO recurrent upper respiratory tract infections. 
 Chronic rhinitis and sneezing due to sinusitis.  
EXCLUSION CRITERIA: 
 More then 12 years. 
 Severe and recurrent epistaxis due to sinusitis. 
 TB rhinitis 
 Congenital anamolies of sinuses. 
 Sinuses agenesis imperfeeta 
 Rhinosporidiasis. 
 
 
 WITHDRAWAL CRITERIA: 
 Exacerbations of symptoms 
 Intolerance to the drug and development of adverse reactions during the drug trial 
any other acute illness. 
 Patients turned unwilling to continue in the course of clinical trial.  
TERMINATION CRITERIA: 
 Not reporting subsequently  
 Voluntary termination.  
Sample Size : 40 patients 
ASSESMENTS AND INVESTIQATIONS CLINICAL ASSESSMENT: 
 Pain and tenderness around nose, between orbit, and maxillary region.  
 Headache associated with vomiting.  
 Fever due to sinusitis. 
 Nasal congestion due to sinusitis. 
 HIO recurrent upper respiratory tract infections.  
 Chronic rhinitis and sneezing due to sinusitis. 
SIDDHA TESTS AND ASSESSMENTS: 
I. UDAL KATTUKAL 
Saaram  
Senneer 
Oonn 
Kozhuppu 
Enbu 
Moolai 
Sukkilam / Suronitham 
 II. ENVAGAI THERVU 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
III. NEERKURI 
IV. NEIKURI 
ROUTINE INVESTIGATION: 
Blood: 
 Total WBC count 
 Differential WBC count 
 ESR 
 HB 
 Absolute Eosinophil count 
SPECIFIC INESTIGATIONS: 
 X – ray : PNS 
 Chest X – Ray PA view 
DATA COLLECTION FORMS 
Required information will be collected from each patients parents / guardian by 
using following forms.  
 
 
 FORMS 
FORM I : Screening and selection proforma. 
FORM IA : History proforma on Enrolment. 
FORM II : Clinical assessment on enrolment. 
FORM II A : Clinical assessment during and after trial 
FORM III : Laboratory Investigation on enrolment and conclusion of  
    trail. 
FORM IV : Consent form 
FORM IV B : Withdrawal form 
FORM IV C : patient information sheet 
FORM IV D : Dietary Advice form 
FORM IV E : Adverse reaction form 
FORM IV F : Discharge proforma 
METHODOLOGY OF TREATMENT :  
STUDY ENROLMENT: 
Patient’s parent or guardian reporting at the OPD with child associated with 
clinical features of nasal discharge, nasal blockage, conjuctival irritation, lacrimation, 
pain and tenderness around nose, below orbit, in the maxillary region, recurrent upper 
respiratory tract infections are chosen for enrolment based on the inclusion criteria. The 
patients who are enrolled are informed about the study trail drug, possible outcomes and 
the objectivies of the study in the language and terms understandable to them and the 
informed consent / Assent form would be obtained from the patient / patient’s parent or 
guardian using consent / Assent form. 
 CONDUCT OF THE STUDY: 
On the first day onwards the trail drug “KANDUPAARANGI CHOORANAM 
(INTERNAL) AND AKIRKATTAI THATLAM (EXTERNAL)”. Will be given for 24 
days. The trail drug will be given in the OPD department of Kuzhanthai Maruthuvam, 
Government Siddha Medical College and Hospital Palayamkottai. The patients will be 
asked to have a regular follow up in the OP department once in 7 days. In each and every 
visit the clinical assessment will be recorded in the prescribed proforma. The laboratory 
investigation will be done before and after treatment and recorded in the prescribed 
format.  
DATA MANAGEMENT 
After enrolling the patients in the study, a separate file for each patient will be 
maintained and all forms will be kept in the file. Study no and patient’s no. will be 
entered on the top of the file for easy identification. Whenever the patient visits OPD 
during the study period, nessary entire, will be made at the assessment forms.  
The screening forms will be filled up separately. The data recordings and adverse 
events, of any, will be monitored by the head of the department and pharmacovigilance 
committee.  
OUTCOME OF TREATMENT: 
PRIMARY OUTCOME: 
Primary outcome is mainly assessed by comparing the reduction in clinical 
symptoms are recurrence before and after treatment.  
SECONDARY OUTCOME: 
Secondary outcome is assessed by comparing the safety parameters before and 
after treatment.  
 
 
 ADVERSE EFFECT / SERIOUS EFFECT MANAGEMENT 
 If the trial patient develops any adverse reaction, he/she would be 
immediately with drawn from the trail and proper management will be given in OPD of 
Govt. Siddha Medical College and hospital Palayamkottai.  
ETHICAL ISSUES: 
1. Informed consent / Assent will be obtained from the patient / patient’s parent or 
guardian after explaining about the clinical trial in an understandable language.  
2. After the consent of the patient (through consent / Assent form) if they fil in the 
Giteria they will be enrolled in the study.  
3. Treatment will be provide free of cost.  
4. Concomitant medicines will be used if there is any need. 
5. The patients who are excluded (as per the exclusion criteria) will be refer to OPD. 
6. The patient’s parents / guardian will be informed about the disease and other 
details of the treatment.  
7. After obtaining the written consent of the patient’s. parents / guardian (through 
consent form in their vernacular language) they will be enrolled in the study.  
8. Treatment would be provided free of cost.  
9. In case of any adverse reactions, the patients will be referred to the OPD of 
Kuzhanthai Maruthuvam department of Govt. siddha medical college hospital, 
palayamkottai for further management.  
10. The patient will be allowed to withdraw from this trial if their parents / guardian 
are not satisfied with this treatment and procedures.  
 
 
 
 
 
 
 ANALYSIS OF TRAIL MEDICINE: 
1. Pharmacological analysis of the trail drug was done at the department of 
pharmacology. K.M. College of pharmacy, Madurai. The details are given in 
annexure.  
2. Bio – chemical analysis was done at the department of Bio – chemistry, 
Government siddha Medical College, Palayamkottai.  
3. Anti microbial study was also done at Malar Micro Diagnostic centre, 
Palayamkottai.  
4. The details and the results are given in the annexure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DRUG REVIEW 
PREPARATION AND PROPERTIES OF TRAIL MEDICINE 
Name of the medicine - Kandupaarangi chooranam(internal) 
                                       Akirkattai Thailam(external) 
 Reference  - Gunapadam Mooligai vaguppu, Pg :216,6 
                 fz;Lghuq;fp #uzk; 
Njitahd ruf;F: 
 fz;L ghuq;fp (Pygmaeopremna  herbecea) -150 gms 
nra;Kiw: 
 ruf;fpid Rj;jpj;J ed;F ,bj;J #uzkhf;fp t];jpufhak; nra;J vLj;J 
nfhs;sTk;  
 msT    : 2-4 gm fhiy> khiy> ,UNtis  
 mDghdk;   : nte;ePh; 
 jPUk;  gpzpfs; : %f;fpy; Kd;ePh;f;Nfhit, gpd;ePh;f;Nfhit:- 
 MAl;fhyk;    : 3 khjq;fs; 
 fz;Lghuq;fp  : Pygmaeopremna herbacea 
 Family   : Verbenaceae 
 gad;gLk; cWg;G : Nth; 
 Rit   : ifg;G 
 jd;ik  : ntg;gk; 
 gphpT   : fhh;g;G 
nra;if : 
 ntg;gKd;lhf;fp 
 jhJntg;ggfw;wp 
 
 
 Fzk;: 
 “fz;Lgh uq;fpnaDQ; rpWNjf Fz;Nly; 
  fhnyq;Nf gpj;jnkq;Nf fge;jh ndq;Nf 
  njhz;Lnjhl;Lj; njhlh;Rthr fhr nkq;Nf 
  Runkq;Nf ntwpnaq;Nf njhdpNeh naq;Nf 
  kpz;L Ghp kPerePh;f; Nfhit naq;Nf 
  ntspePUz; zPnuq;Nf tpww;fh nyq;Nf 
  Mz;Lglhr; rPjRuq; fLg;G nkq;Nf 
  aoiyaf Nenaq;Nf aiwF tPNu” 
CHEMICAL CONSTITUENT: 
 Saponins oleanolic acid d-mannitol 
ACTIVITY: 
 Antipyretic, Anti - inflammatory 
 
 
 
 
 
 
 
 
 
 
 
 
 
fz;Lghuq;fp 
 
 
 
 
 
 
 
 
fz;Lghuq;fp R+uzk; 
 
 
 
 
 
 
 
 
 
 AKIRKATTAITHAILAM (EXTERNAL) 
mfpw;fl;il ijyk;: 
Njitahd ruf;Ffs;: 
1. mfpw;fl;il ( Aquilaria agallocha )    - XU gyk;  (35 gm) 
2. ey;nyz;nza; ( Gingelly  oil)   - XU gb (1.3Lit) 
3. gRk;ghy; ( Cow milk)     - xU gb  (1.3.lit) 
4. mjpkJuk; ( Glycyrrhiza glabra )   - xU gyk;  (35 gm) 
5. jhd;wpf;fha;Njhy; ( Terminalia Bellirica )  - xU gyk; ( 35gm) 
nra;Kiw:- 
 mfpw;fl;ilf;  FbePh;> ey;nyz;nza;> gRtpd;ghy; tiff;F xU gb vLj;J 
gRtpd; ghy; tpl;liuj;Jf; fye;J vhpj;J kzy; gjj;jpy; vLj;Jf;  nfhs;sTk;  
jPUk; Neha; 
 mfpw;fl;ilj; ijyj;ij Kbj;ijykhf gad;gLj;j ePh;f;Nfhit, Nkfk; 
%f;filg;G Kjypa Neha;fs; ePq;Fk;  
Mal;fhyk;:-  
 xU Mz;L  
 mfpw;fl;il   - Aquilaria Agallocha 
 Family   - Thymeleacea 
 gad;gLk; cWg;G - fl;il 
 Rit   - fhh;g;G> ifg;G> rpW ,dpg;G 
 jd;ik  - ntg;gk; 
 gphpT   - ,dpg;G 
nra;if: 
 ntg;gKz;lhf;fp 
 gpj;jePh;ngUf;fp 
 tPf;fKUf;fp 
 
 Fzk;:-  
 “ehrpailg;G etputpb jhSNeha; 
  tPR eikg;Gilfs; tpl;NlFk; - Ngrpy; 
  RfU kaq;Fe; JizKiyaha; ey;y 
  mfU kuj;jh ywp 
  jsh;e;j tpUj;jUf;fhe; jf;f   kzj;jhy; 
  cise;j Rukidj;J NkhLk; - tsh;e;jpfOk; 
  khNd mfpw;Giff;F the;jpa Nuhrfk;Nghk; 
  jhNd jsh;r;rpAWQ; rhw;W” 
CHEMICAL CONSTITUENT:- 
 Agarospirol, Aquillicochin, Holocellose, Lingnan, Pentosan, Essential oil 
 
ACTIVITY:-  
 Anti - pyretic, Analgesic and anti oxidant 
mjpkJuk;  - Glycyrrhiza glabza 
Family   - Fabaceae 
gad;gLk; cWg;G - Nth; 
Rit   - ,dpg;G ,ifg;G 
jd;ik  - jl;gk; 
gphpT   - ,dpg;G 
nra;if: 
 cs;soyhw;wp 
 Nfhioafw;wp 
 cukhf;fp 
 
 
 Fzk;:  
 “jpj;jpf;F kjpkJuf; Fzj;ijnaLj;J iuf;fpy; 
  rpukaf;fQ;Rujhfe; jphpNjhlq;fs; gpj;jQ;rj;jpf;FkpJ 
  Gife;njLf;Fk;Nrl;Lkj;ijg;  gpj;jNuhfj;ij 
  mj;jpg;gpw;wpdNkfe;jd;idth je;jpidaWj;jpLk;” 
CHEMICAL CONSITUENTS:- 
 Beta glycyrrhetinic acid  liquiritigenine, disodium, glycyrohetinic acid, glycyricin 
ACTIVITY:- 
 Immuno modulator, Anti -viral, anti -tussive, antioxidant, anti -microbial, 
Hepatoprotective 
 jhd;wpf;fha;   -   Terminalia bellirica 
 Family   - Combrectaceae 
 gad;gLk; cWg;G - Njhy; 
 Rit   - Jth;g;G 
 jd;ik  - ntg;gk; 
 gphpT   - ,dpg;G 
nra;if:- 
 Jth;g;gp 
 Nfhioafw;wp 
 kykpsf;fp 
 cukhf;fp 
Fzk;:- 
 “rpye;jptplk; fhkpag;Gz; rPohd Nkfq; 
   fye;JtUk; thjgpj;jq; fhNyh - lyh;e;J lypy; 
   Cd;wpf;fha; ntg;gKjpugpj; Jq;fuf;Fe; 
   jhd;wpf;fha; ifapnyLj; jhy; 
    Mzp;g;ngz; Nkdpf; foFk; xspAkpFk; 
   Nfhzpf;nfhs; thjgpj;jf; nfhs;ifNghk;-jhdpf;fha; 
   nfhz;lth;f;F NkfkWk; $wh mdw;wzpAk; 
   fz;lth;f;f thjk;Nghk; fhz;” 
 
CHEMICAL CONSTITUNET:-  
 Termilignan, Thannilignan, anolginan  B identified 
 
ACTIVITY:- 
 Analgesic, Antiallergenic, Antibronchitic, Anti-inflammatory, Antioxidant, 
Antiperoxident, Antiviral, Brochodilator, Immunosuppresant, Astringent.   
 
 
 
 
 
 
 
 
 
 
 
 
DRUGS FOR AKIRKATTAI THAILAM 
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 RESULTS AND OBSERVATION 
RESULTS WERE OBSERVED WITH RESPECT TO THE FOLLOWING 
VITERIA 
1. Age distribution  
2. Sex distribution 
3. Religion distribution 
4. Informant 
5. Diet 
6. Social environmental status 
i. Parent’s occupation 
ii. Socio – economic status 
7. Paruvakaalangal 
8. Thinaigal 
9. Aetiological Factors 
10. Mode of onset 
11. Clinical Features 
12. Family history 
13. Uyir Thathukkal 
14. Udal thathukkal 
15. Envagai Thervugal 
16. Nei Kuri 
17. Investigation 
18. Result. 
For this study results 20 In – patients and 20 out – patients were selected. 
 
 
1. AGE DISTRIBUTION:-   
Sl.No. Age No. of Cases Percentage 
1. 
0 – 1 Year 
Kaapu and Chenkeerai 
- - 
2. 
1 – 3 Years Thaalaattu, 
Sappaani, Mutham, Varugai 
- - 
3. 
3 – 6 
Years Anbuli, Chitril, 
Chiruparai, Chiruther, Paethai 
(Female) and 
Pillai (Male) Paruvam 
4 10% 
4. 
6 – 12 years 
Paethumbai (Female) 
Chiruparuvam (Male) 
36 90% 
 
 
Inference: 
 Therefore the above table indicates that children under the age group of 3 
years to 6 years (10%) are mostly affected, 90% childrens are affected in the age group of 
6 years – 12 years.  
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2. Sex Distribution:  
l.No. Sex 
No. of 
Cases 
Percenta
ge 
1. Male 20 50% 
2. Female 20 50% 
 
 
 
 
INFERENCE: 
 Among 40 cases of study 20 were male children (50%) and 20 were 
female children (50%) both childrens are equally affected.  
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3. RELIGION DISTRIBUTION: 
l.No. Religion 
No. of 
Cases 
Percenta
ge 
1. Hindu 27 6.75% 
2. Christian 6 15% 
3. Muslim 7 17.5% 
 
 
 
 
 
 
 
 
 
INFERENCE: 
 Out of 40 cases 67.5% were Hindus 15% were Christian and 17.5% were 
Muslim.  
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4. INFORMANT: 
l. 
No. 
INFORMANT No. of Cases 
Percentag
e 
1. Mother 28 70% 
2. Father 11 27.5% 
3. Grand parents 1 2.5% 
4. Others 0 0% 
 
 
 
 
 
 
 
 
 
INFERENCE: 
 According to this 70% of cases were good reliability 27.5% of cases fair 
reliability, 2.5% of cases not reliable.  
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5. DIET: 
l. 
No. 
Food habit 
No. of 
Cases 
Percenta
ge 
1. Vegetarian 6 15% 
2. Mixed 34 85% 
 
  
 
 
 
 
 
 
 
INFERENCE: 
 Out of 40 cases 15% were vegetarian and remaining 85% mixed diet.  
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6. SOCIAL ENVIRONMENTAL STATUS: 
I. PARENTS OCCUPATION 
l. 
No. 
Grade 
Occupation No. of 
Cases 
Perce
ntage 
1.  Class – I 
Executives 
0 0% 
2.  Class – II 
Professional 
4 10% 
3.  Class – III 
Trained 
workers 6 15% 
4.  Class – IV 
Untrained 
workers 30 75% 
 
 
 
 
 
 
 
 
INFERENCE: 
Out of 40 cases, 75% of cases were children of untrained workers.  
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II. SOCIO ECONOMIC STATUS: 
l. 
No. 
Socio Economic Status No. of Cases Percentage 
1. Poor  30 75% 
2. Middle class 10 25% 
3. Rich 0 0% 
 
 
 
 
 
 
 
 
 
INFERENCE:  
 Parent’s occupation and socio – economic status may be reason while the 
patients were predisposed to develop Neer Peenisam. 
 
 
 
7. DISTRIBUTION OF PARUVA KAALANGAL: 
l. No. Paruva Kaalangal 
No. of 
Cases Percentage 
1. Kaar (Aavani, Purattai) (August – October) 0 0% 
2. Koothir (Ayppasi, Karthigai) (October - December) 0 0% 
3. Munpani (Maarkazhi, Thai) (December - February) 21 52.5% 
4. Pinpani (Maasi, Pankuni) (February - April) 8 20% 
5. Elavenil (Chithirai, Vaikasi) (April - June) 11 27.5% 
6. Muthu venil  (Aaani, Aadi) (June - August) 0 0% 
 
 
INFERENCE 
 Among the patients, 52.5% of the disease comes under the muntani kaalam 
and 20% of the incidence comes under the pinpanikaalam 27.5% in Elaveni kaalam.  
The prevalence of disease under munpani kaalam, pinpani kaalam and Elavenil 
Kaalam. 
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8. DISTRIBUTION OF LANDS (THINAIGAL) 
Sl.NO. 
Thinai No. of Cases 
Percenta
ge 
1 
Kurinji (hill) 0 0% 
2 
Mullai (Forest) 0 0% 
3 
Marutham (Fertile) 30 75% 
4 
Neithal (Coastal) 10 25% 
5 
Paalai (Desert) 0 0% 
 
 
INFERENCE:  
According to siddha concept, no disease occur to the people living in marutham, 
but today’s people entirely differs for their ancestors both in dietary and other habits. And 
also the study was conducted in and around Tirunelveli, a marutham land and neithal 
land. So majority of the cases in from the marutham land. 
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9. AETIOLOGICAL FACTORS: 
l. 
No. 
Aetiological Factors No. of Cases 
Percentag
e 
1. Dust and smoke  3 7.5% 
2. R.S. Infection and dust 14 35% 
3. Husks of grain 56 12.5% 
4. R.S. infection and cold exposure 16 40% 
5. Husks of grain and cold exposure 2 5% 
 
 
INFERENCE 
Among the In – patients, 40% of the patients respiratory infection and dust 
exposure 35% of the patients had respiratory infection and cold exposure, 12.5% of the 
patients had husks of grain exposure and 7.5% of the patients and dust and smoke 
exposure; and 5% hashusks of grains and cold exposure collectively. 
Above showed that dust respiratory infections and cold exposure were the main 
aetiological factors among these children. 
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10. MODE OF ONSET: 
Sl. No. Mode of onset No. of Cases Percentage 
1.  Sudden 22 55% 
2.  Gradual 18 45% 
 
 
 
INFERENCE: 
 The signs and symptoms of patients with Neer Peenisam. 
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11. CLINICAL FEATURE: 
The signs and symptom of patients with Neer peenisam. 
Sl. No. Signs and Symptoms No. of Cases Percentage 
1 Running Nose 26 65% 
 2 Sneezing 30 75% 
3 Cough with expectoration 20 50% 
4 Fever 10 25% 
5 Poor appetite 5 12.5% 
6 Diarrhoea 0 0% 
 
 
INFERENCE: 
 Major clinical symptoms reported to be running nose and sneezing (90%) 
after treatment it was reduced 65% of cases had running nose before treatment after 
treatmentit was reduced to 75% 12.5 cases had poor diet intafe, it was reduced to 2% 
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respectively 75% of cases had sneezing, it was reduced to 5% and most of the other 
clinical signs were relieved after treatment.  
12. FAMILY HISTORY: 
l. 
No. 
Family History 
No. of 
Cases 
Percentag
e 
1. Positive 16 40% 
2. Negative 24 60% 
 
 
 
 
 
 
 
 
INFERENCE: 
 Out of 40 cases, 16 (40%) cases have positive family history and 24 (60%) 
cases have negative family history.  
 
 
13. UYIR THATHUKKAL: 
A. DERANGEMENT OF VATHAM: 
L. 
NO. 
TYPES OF VATHAM NO. OF CASES 
PERCENTA
GE 
1.  Pranan (gpuhzd;) 25 62.5% 
2.  Abanan (mghzd;) 0 0% 
3.  Viyanan (tpahdd;) 25 62.5% 
4.  Uthanan (cjhdd;) 25 62.5% 
5.  Samanan (rkhdd;) 0 0% 
6.  Nagan (ehfd;) 4 10% 
7.  Koorman ($Hkd;) 10 25% 
8.  Kirukaran (fpUf;fud;) 30 75% 
9.  Devathathan (Njtjj;jd;) 0 0% 
10.  Dhananjeyan (jdQ;nrad;) 0 0% 
 
 
INFERENCE: 
Out of 40 cases, pranan, viyanan, uthanan, Nagan, koorman, kirukaran were 
affected in all the 100% of patients Nagan was affected 10% of the patients and kirukaran 
was affected in 80% of the patients. 
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b. DERANGEMENT OF PITHAM: 
 
Sl. No. Types of Pitham 
No. of 
Cases 
Percenta
ge 
1.  Analagam (mdyk;;) 0 0% 
2.  Ranjagam (,uQ;rfk;) 0 0% 
3.  Saathagam (rhjfk;) 8 20% 
4.  Pirasagam (gpuhrfk;) 10 25% 
5.  Aalosagam (MNyrfk;) 0 0% 
 
 
INFERENCE: 
Pirasagam was affected 25% of patients, saathagam was affected in 20% of the 
patients.  
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C. DERANGEMENT OF KABAM 
Sl. 
No. 
Types of Kabam No. of Cases 
Perce
ntage 
1 Avalambagam (mtyk;gfk;) 25 62.5% 
2 Kilethakam (fpNyjfk;) 0 0% 
3 Pothagam (Nghjfk;) 0 0% 
4 Tharpakam (jw;gfk;) 10 25% 
5 Santhikam (re;jpfk;) 0 0 
 
 
INFERENCE: 
 Avalambagam was affected in 62.5% of the patient in the disease and 25% 
santhikam was affected of the patient in the disease. 
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14. UDAL THATHUKKAL: 
l. 
No. 
Udalthathukkal No. of Cases Percentage 
1.  Saaram (rhuk;) 40 100% 
2.  Senneer (nre;ePH) 24 60% 
3.  Oon (Cd;) 0 0% 
4.  Kozhuppu (nfhOg;G) 0 0% 
5.  Enbu (vd;G) 0 0% 
6.  Moolai (%is) 0 0% 
7.  Sukkilam/ Suronitham (Rf;fpyk; / RNuhzpjk;) 0 0% 
 
INFERENCE: 
 Among the 40 patients saaram was affected in 100% of the patients and 
senneer was affected in 60% of the patients. 
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15. ENVAGAI THERVUGAL: 
l. 
No. 
Udalthathukkal No. of Cases Percentage 
1.  
Naadi (ehb) 
thjgpj;jk; 
a. thjfgk; 
b. gpj;j fgk; 
6 
18 
14 
15% 
45% 
35% 
2.  Sparesam (];ghprk;) 10 25% 
3.  Naa (eh) 10 25% 
4.  Niram (epwk;) 4 10% 
5.  Mozhi (nkhop) 0 0% 
6.  Vizhi (tpop) 8 20% 
7.  Malam (kyk;) 0 0% 
8.  Moothiram (%j;jpuk;) 0 0% 
 
INFERENCE: 
 Among the 40 cases, sparisam affected in 25% of the patients, Naa 
affected in 25% of the patients, Niram affected in 10% of the patients. Vizhi affected in 
20% of the patients. 
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16. NEIKURI: 
l. No. 
Character of 
Urine 
Neikuri 
Reference 
No. 
of cases 
Percen
tage 
1. 
Spreads like 
snake 
Vathaneer 8 20% 
2. Spreads like Ring Pitha neer 10 25% 
3. Spreads likePearl Kaba neer 22 55% 
 
 
 
INFERENCE: 
 Vatha neer observed in 8 (20%) of cases; pitha neer observed in 10 (25%) 
of cases and kaba neer observed in 22 (55% of) cases. 
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17. RESULTS 
Among 40 cases, the results were observed as follows, 
Sl.No. Result No.Of Cases (Out 
of 40) 
Percentage 
1 Good 34 85% 
2 Moderate 6 15% 
 
 
Inference :  
 85% showed good results and 15% showed moderate response, these results are 
based on the clinical improvement. 
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 OUT PATIENTS RECORD 
S. 
No 
OP.No Name Age/Sex No of 
days 
Treated 
Treates 
Stated 
Date 
Remarks 
1. 1578 Sandhana Kumar 11yrs/MC 24 days 5.1.16 Good 
2 7534 Ithris Mohammed 7yrs/MC 28days 23.1.16 Good 
3 9618 Kabees Absal 
hameed 
12yrs/Mc 28 days 29.1.16 Fair 
4 9873 Indumathi 10yrs/Fc 24days 30.1.16 Good 
5 9999 Jaya 8yrs/Fc 24 days 30.1.16 Good 
6 10046 Blessy 12/Fc 24days 30.1.16 Good 
7 10047 grazy 8/Fc 24days 30.1.16 Fair 
8 10504 Sandhiya 7yrs/Fc 28 days 1.2.16 Good 
9 11295 Sheeba 7yrs/Fc 24 days 3.2.16 Good 
10 14760 Hatheesha 8yrs/Fc 28days 13.2.16 Good 
11 15569 Sandhanam 11yrs/MC 24days 16.2.16 Good 
12 16898 Sowmiya 10yrs/Fc 24 days 19.2.16 Fair 
13 17189 Valimuthu 8yrs/Fc 24 days 20.2.16 Good 
14 17709 Muthu Krishnan 11yrs/Mc 24 days 22.2.16 Good 
15 17544 Kiruba 7yrs/Fc 28days 22.2.16 Good 
16 19561 Mohammed ithris 11yrs/Mc 24 days 27.2.16 Fair 
17 19541 Abishek 12yrs/Mc 28days 27.2.16 Good 
18 19954 Akshaya 8yrs/Fc 24 days 29.2.16 Good 
19 22203 Vegatesh 12yrs/Mc 24days 7.3.16 Good 
20 22859 Thasleema 8yrs/Fc 24days 9.3.16 Good 
 
 
  
INPATIENTS CASE SHEET REPORT 
S.
No 
IP No Name of 
patient 
Age/sex Duration 
of illness 
Signs and symptoms Admissio
n date 
Discha
rge date 
No.of 
days 
Treated 
Result 
1 158 Ithris 7/MC 3 months  Cold, cough , sneezing,running nose , headache 24/01/16 04/02/16 11 Moderate 
2. 223 Sophia 8/FC 1 month Fever,cold, cough, sneezing,running nose , headache 29/02/16 16/02/16 18 Good 
3. 272 Gowtham 12/ MC 4 months Cold, cough , sneezing,running nose , headache 22/02/16 10/03/16 19 Good 
4. 585 Senbagav
alli 
10/FC 20 days Cough with expectoration, running nose ,head ache 03/03/16 10/03/16 07 Good 
5. 664 Benit 12/MC 2 months Cold, cough , sneezing,running nose , headache 10/03/16 28/03/16 18 Good 
6. 713 Ramya 06/FC 1 month Fever,cold, cough, sneezing,running nose, headache 16/03/16 23/03/16 07 Good 
7. 835 Dalfin 7 / MC 3 months Cough with expectoration, running nose ,head ache 28/03/16 13/04/16 16 Good 
8. 1145 Mukesh 6 / MC 20 days Cold, cough , sneezing,running nose, headache 29/04/16 18/05/16 20 Good 
9. 1153 Dinesh 10/MC 1month Fever, cold, cough, sneezing,running nose, headache 30/04/16 18/05/16 19 Good 
10. 1222 Harivigne
sh 
12/ MC 2 months Cough with expectoration, running nose ,head ache 07/05/16 02/06/16 26 Good 
11. 1133 Arjun 6 / MC 10 days  Fever, cold, cough, sneezing, running nose, 
headache  
20/05/16 03/06/16 14 Good 
12. 1387 Anuvinay
a 
12 / FC 2 weeks Fever, body pain, nasal polyp, headache 26/05/16 03/06/16 8 Good 
13. 1391 Subin 12/MC 1 week Cough with expectoration, running nose ,head ache 26/05/16 03/06/16 8 Good 
 INFERENCE: 
  The above all 20 cases of Inpatients, Neer Peenisam had been very well response with Kandupaarangi chooranam (internal) 
and Akirkattai thailam(external). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14. 1388 Anunavee
na 
7 / FC 1  month Fever, body pain, nasal polyp ,headache 26/05/16 06/06/16 11 Good 
15. 1453 Madhesh 7/ MC 2 months Cold , sneezing , headache with vomiting 02/06/16 12/06/16 10 Good 
16. 1523 Jeevitha 8 / FC 1 month Cold, cough , sneezing,running nose , headache 11/06/16 17/06/16 6 Good 
17. 1524 Rakesh 9 / MC 20 days  Fever, body pain, nasal polyp ,headache 11/06/16 17/06/16 6 Moderate 
18. 1546 Ramesh 12/MC 1 month Cough with expectoration , running nose ,head ache 14/06/16 22/06/16 8 Good 
19. 1547 Shanthi 9 / FC 15 days Cough with expectoration , running nose ,head ache  14/06/16 22/06/16 8 Good 
20. 1548 Fathima 6/FC 10 days Fever, body pain, nasal polyp ,headache 14/06/16 22/06/16 8 Good 
 LABORATORY INVESTIGATIONS 
BT – Before Treatment,   AT -  After Treatment, P – Polymorphs,  L – Lymphocytes, E-Eosionophils,   ESR – Erythrocyte 
Sedimentation Rate, Hb - Haemoglobin A- Albumin, S – Sugar, D – Deposits,N - Nil 
S.No. 
P.No 
Name of the 
patient 
i. Haematological Investigation Urine Analysis Motion Analysis 
WBC Total Count cells /  
cu.mm 
WBC differential count ESR – mm/ Hr Hb gm% Before Treatment After Treatment Before 
Treatment 
After 
Treatment 
BT AT BT AT A S D A S D Ova Cyst Ova Cyst 
BT AT P% L% E% P% L% E% ½ hr 1hr ½ hr 1hr BT AT N N N N N N N N N N 
1 
58 
Ithris 10000 10050 44 44 9 44 48 4 6 12 4 8 12 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2 
23 
Sophia 10000 9500 52 39 7 58 39 2 9 18 5 10 10 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3 
72 
Gowtham 9000 8800 59 38 3 50 48 2 3 6 3 6 11 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4 
85 
Senbagavalli 8600 8800 55 35 10 55 40 5 7 14 6 12 12 13 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5 
64 
Benit 10000 10100 53 44 2 50 47 1 5 10 4 8 9 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6 
13 
Ramya 9500 9600 62 30 8 62 33 3 10 20 6 12 10.4 10.5 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7 
35 
Dalfin 9400 9200 58 36 6 54 42 2 6 12 5 10 12.1 12.6 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8 
145 
Mukesh 10200 10100 56 37 7 60 35 1 8 16 7 14 10.3 10.8 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9 
153 
Dinesh 9750 9800 59 34 4 64 32 1 11 22 9 18 10.2 11.6 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10 
222 
Harivignesh 8600 8700 48 40 8 54 44 2 7 14 6 12 11 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11 
133 
Arjun 10100 10100 60 35 2 60 38 2 12 24 7 14 10 10.9 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12 
387 
Anuvinaya 9800 9600 50 41 6 50 46 3 11 22 8 16 11.2 11.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13 
391 
Subin 9000 9100 44 44 9 47 46 5 5 10 4 8 9.9 10.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14 
388 
Anunaveena 11200 11400 60 32 8 62 36 2 10 20 9 18 10.3 10.9 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15 
453 
Madhesh 8800 9000 59 36 5 60 36 2 9 18 5 10 12.2 12.8 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16 
523 
Jeevitha 8300 8400 60 34 6 61 36 3 6 12 6 12 11 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17 
524 
Rakesh 9200 9400 48 43 7 51 46 2 11 22 7 14 9.1 10.9 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18 
546 
Ramesh 8500 8600 52 40 8 58 40 2 6 12 4 8 11.5 12.3 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19 
547 
Shanthi 8800 9000 62 30 8 62 35 3 12 24 6 12 9.5 10.8 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
20 
548 
Fathima 9500 9600 60 33 5 60 38 1 6 12 6 12 10 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
 ABSOLUTE  EOSINOPHIL COUNT DETAILS 
 
 
S.NO 
 
OP.NO NAME AGE/ SEX AEC(BT) AEC(AT) 
01. 10047 Grazy 8yrs/Fc 440 380 
02. 10504 Sandhiya 7yrs/Fc 620 376 
03. 11295 Sheeba 7yrs/Fc 520 410 
04. 14760 Hatheesha 8yrs/Fc 480 690 
05. 15569 Sandhanam 11yrs/Mc 980 355 
06. 16898 Sowmiya 10yrs/Fc 340 320 
07. 17189 Vallimathi 8yrs/Fc 435 324 
08. 17709 Muthu Krishnan 11yrs/Mc 490 610 
09. 19954 Akshaya 8yrs/Fc 540 378 
10. 17544 Kiruba 7yrs/Fc 728 480 
 
 
 
 
 
 
 
 DISCUSSION 
According to Siddha texts, Neer Peenisam is an ailment of childhood and  the 
disease is predominantly concerned with the Sinusitis in children .In  this  study  40  
cases  were  treated  at  the  post  graduate  department.  Siddha methods  of  diagnosis  
were  carried  out  and  recorded  in  the  selection  Proforma, and  the  diagnosis  was  
confirmed  with  the  help  of  modern  investigations.  The patients  were  treated  
with  the  drug  Kandupaarangi chooranam (internal) and Akirkattai thailam 
(external) and  clearly observed.  The  observations  are  discussed  here  under.  
1. DISTRIBUTION ACCORDING TO AGE: 
This  study  indicates  that  children’s  under  the  age  group  of  6-12  years 
(90%)  are  mostly  affected  since  they  contribute  to  school  going  age  they may  
be  exposed  to  a  variety  of allergens.     
2. DISTRIBUTION ACCORDING TO SEX: 
Among 40 cases of study 50% were male children and 50% were female 
children.  
3. DISTRIBUTION ACCORDING TO SOCIO ECONOMIC STATUS: 
Most of the patients  (75%)  belonged  to  low  income  group,  25  %  of  the 
cases were  middle  income  group .  Due  to  poverty,  malnutrition,  overcrowding  
and  unhygienic  practices this  disease  is  more  prevalent  among  the  poor.   
4. DISTRIBUTION OF PARUVA KAALANGAL: 
According  to  paruvakaalam  the  highest  distribution  (52.5%)  was  noticed  
in Munpani  kaalam,  12.5%  of patients  are  affected  in  Kaar  kaalam,20%  of  
patients  are  affected  in  Pinpani kaalam  and  27.5%  in  affected  in  Elavenil  
kaalam.  
 
 
 5. DIET HISTORY:     
According to diet history 85% of cases had mixed diet, and 15% had 
vegetarian diet. The highest incidence of cases was observed in mixed diet of food 
habits.           
6. FAMILY HISTORY:         
According to family history 40% of the cases had positive family history, and 
60% of the cases had no relavent history. The highest incidence of cases had positive 
family history. 
 7. DISTRIBUTION OF LAND:       
Among the selected cases 25% of them were from Neithal land and 75% of 
them were from Marutham land. This is due to the fact that the study was conducted 
at Chennai, a Neithal land and so majority of the cases were from that land.          
8. DISTRIBUTION ACCORDING TO UYIR THATHUKKAL:         
 i. Derangement of Vatham:        
 Due to derangement of vatham, the following symptoms may occur. Pranan 
(62.5%) causes difficulty in breathing. Viyanan (62.5%) , uthanan (62.5%) causes 
cough,  Naagan was deranged in (20%) of cases as some patients had difficulty in 
playing and other activities, koorman was deranged in (25%),kirukaran was deranged 
in(75%)of cases cause cough, running nose .                
ii. Derangements of Pitham:          
 Saathagam was deranged in 20% of patients causing imitations in their daily 
physical activities, and Prasagam was deranged in 25% of cases.            
 
 
 
 iii) Derangements of Kabam:          
Due to derangements of kabam, Avalambagam was deranged in 62.5% of 
patients causing wheezing and difficulty in breathing, Tharpakam was deranged in 
(25%) of patients .        
9. DISTRIBUTION ACCORDING TO EZHU UDAL KATTUGAL:     
 In ezhu udal kattugal, saaram (100 %), seneer (60%), of cases were affected       
10. ENN VAGAI THERVUGAL:        
According to this study, Naa was affected in 25 % of cases (coated and pallor), 
Sparisam was affected in 25 % of cases (fever), Niram was altered in 10 % of patients 
due to anaemia, Vizhi was affected in 20 % of cases causing pallor, 45% of cases had 
Vadhakaba naadi, 15% of cases had vadha pitha naadi & 35% of cases had pithakaba 
naadi,were affected.       
11. NEI KURI:        
 In this study most of the patients had kaba neer (55%) which stood as a pearl 
indicating that the most predominant manifestation of this disease is kabam.      
12. DISTRIBUTION ACCORDING TO AETIOLOGICAL FACTORS:     
 Respiratory infections contribute to 40% of the most common aetiological 
factors, dust exposure 35% of cases were affected by respiratory infection and cold 
exposure,12.5%of the cases had husks of grain exposure and 7.5% of the cases dust 
and  smoke exposure, and 5%  had husks of grains and cold exposure collectively.  
13. DISTRIBUTION OF CLINICAL FEATURES:      
 Major clinical symptoms reported to be running nose and sneezing 90% after 
treatment it was reduced to 65%of cases had running nose before treatment and after 
treatment was reduced to 75%.12.5%cases had poor diet intake, it was  reduced to 2% 
respectively.75%of cases had sneezing ,it was reduced to 5%and most of the other 
clinical signs were relieved after treatment.     
 14. LAB INVESTIGATION:       
According To Modern Aspect 
Laboratory investigation  
     Each and every patient was insisted to undergo lab investigation . The details 
about the investigations are enclosed. Routine examination of blood and urine and 
motion were done before and after treatment. In most of the cases (80%) elevated 
Absolute Eosinophil count was decreased after treatment .       
Treatment  
 The trial medicine for the treatment of Neer Peenisam were 
“Kandupaarangi Chooranam ” administered orally with hot water and Akirkattai 
Thailam externally. 
15. BIOCHEMICAL ANALYSIS:     
     Qualitative analysis of the trial drug revealed the presence of ferrous iron which is 
more soluble and readily absorbable form that in treating children who are associated 
with anaemia. The study also indicates the presence of chloride, calcium, alkaloid, 
starch and reducing substances etc.                             
16. PHARMACOLOGICAL ANALYSIS:        
 Pharmacological analysis showed the drug has significant anti inflammatory 
antihistamine activity.   
17.  RESULT:        
 Satisfactory improvement was reported in 7 days of commencement of 
treatment. Out of 40 cases 34 patients (85%) showed Good response with remarkable 
relief of symptoms, frequency of similar episodes is reduced and improvement in 
school attendance. Moderate result was observed in 6 cases (15%) with reduction in 
signs and symptoms.   
 SUMMARY 
 
The aim of this dissertation subject is to cases  the efficacy of trail drug 
“Kandupaarangi Chooranam”  (Internal) and Akirkattai thailam  
(External) for Neer Peenisam without any adverse effects. 
The Etiopathogenesis and symptoms of Neerpeenisam have been 
corelated with that of sinusitis in children disease with evidence of literature. 
Clinical diagnosis and selection of cases was based on clinical features 
decribed in siddha text book and also using Questionnarie. 
The medicine chosen for Treatment and management of Neer Peenisam 
was Kandupaarangi Chooranam 2-4gm with hot water internally; twice a 
day and Akirkattai thailam for use mudithailam (head bath) Externally. 
The trail drug selection is based on its siddha pharmacological action to 
pacify the dernanged vathem, pitham and kabam and also due to its immune 
modulatory effect of ingrediants.  
Forty children were diagnosed with Neerpeenisam clinically and they 
were observed for clinical diagnosis, laboratory diagnosis, during the treatment 
and the results were dealt in the proforma. 
All the patients were kept under strict dietary control during the 
treatment the observation on effect of therapy was encouraging.  
Laboratory diagnosis was done by modern methods of examinations. 
The treatment covers Administration of trail drug according to the age 
and also includes Pranayama, Yogasana, Mudra, educating the patients and 
their parents about sinusitis in children disease and  management adherenee to 
treatment and dispel fear and misconceptions. 
 The documentation of observation made during the clinical study 
showed that the drug is clinically effective.  
Antibacterial activity of “Kandupaarangi Chooranam” showed that it 
inhibited the growth of bacterial strain against streptococcus pheumonia. 
In the phoamaadogical analysis, the train drug “Neerpeenisam” had 
significant Anti – Histamine, Anti – inflammatory action which by the virtue of 
controlling the airway hyper responsiveness help to improve the patients 
quality of life. 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
The Respiratory Allergies in children, increasing prevalence and its.   
impact in reducing the quality of life in children has prompted the author to 
choose an effective drug without any side effects, it is believed to improve the 
quality of life in childrens. 
The treatment of  “Neerpeenisam”, “Kandupaarangi Chooranam” 
has showed good response with no adverse effect and ensure to be safe, 
effective and simple to administration.  The ingredients of maantha ennai are 
feasible and useful, these compounds may serves  as potentially useful drug at 
lower cost. 
Statisticaly it is concluded that the treatment was effective and 
significant, clinical results were found to be significant good Improvement was 
found in 85% of cases moderate in 15% of cases. 
Therefore it is concluded that the trail drug “Neerpeenisam” alond with 
the modalities of pranayama, Yogasana, Mudra and patients education will 
benefit the society and meet patients and familys expectations of satisfactory 
care in children. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 ANNEXURE - II 
BIO-CHEMICAL ANALYSIS OF KANDUPAARANGI CHOORANAM 
PREPARATION OF THE EXTRACT: 
 5gms of the drug was weighed accurately and placed in a 250ml clean 
beaker then 50ml of distilled water is added and dissolved well. Then it is 
boiled well for about 10 minutes. It is cooled and filtered in a 100ml volumetric 
flask and then it is make up to 100ml with distilled water.  This fluid is taken 
for analysis. 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared 
extract is taken in a clean test tube. To 
this add 2ml of 4% Ammonium 
oxalate solution 
No white 
precipitate is 
formed 
Absence of 
calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 5% 
Barium chloride solution. 
No white 
precepitate is 
formed 
Absence of 
sulphate 
3.  TEST FOR CHLORIDE 
The extract is treated with silver 
nitrate solution 
No white 
precipitate is 
formed 
Absence of 
chloride 
4. TEST FOR CARBONATE 
The substance is treated with 
No Brisk 
effervescence is 
formed 
Absence of 
carbonate 
 concentrated Hcl. 
5. TEST FOR STARCH 
The extract is added with weak 
iodine solution 
Blue colour is 
formed 
Indicates the 
presence of 
starch 
6.  TEST FOR FERRIC IRON 
The extract is acidified with 
Glacial acetic acid and potassium ferro 
cyanide. 
 No blue colour is 
formed 
Absence of 
ferric iron 
7. TEST OF FERROUS IRON  
The extract is treated with 
concentrated Nitric acid and 
Ammonium thiocyanate solution 
Blood red colour is 
formed 
Indicates the 
presence of 
ferrous iron 
8.  TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid 
No Yellow 
precipitate is 
formed 
 Absence of 
phosphate 
9.  TEST FOR ALBUMIN 
The extract is treated with 
Esbach’s reagent 
No Yellow 
precipitate is 
formed 
Absence of 
Albumin 
10.  TEST FOR TANNIC ACID 
The extract is treated with 
ferric chloride. 
Blue black 
precipitate is 
formed 
Indicates the 
presence of 
tannic acid 
11.  TEST FOR UNSATURATION 
Potassium permanganate 
It gets 
decolourised. 
Indicates the 
presence of 
unsaturated 
compound 
 solution is added to the extract  
12.  
TEST FOR THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and add 
8-10 drops of the extract and again 
boil it for 2 minutes. 
No colour change 
occurs. 
Absence of 
Reducing 
sugar 
13.  TEST FOR AMINO ACID 
One or two drops of the extract 
is placed on a filter paper and dried 
well. After drying, 1% Ninhydrin is 
sprayed over the same and dried it 
well. 
Violet colour is 
formed 
Indicates the 
presence of 
Amino acid 
14. TEST FOR ZINC 
The extract is treated with 
Potassium Ferrocyanide. 
No white 
precipitate is 
formed 
Absence of 
Zinc. 
INFERENCE: 
  The extract prepared from the given sample contains starch, 
ferrous iron, tannic acid, unsaturated compound and amino acid. 
 
 
 
 
 
 ANTI-INFLAMMATORY ACTIVITYOF SIDDHA 
PREPARATION KANDU PARANGI CHOORANAM 
The anti-inflammatory activities of siddha preparation kandu parangi 
chooranam   at a dose of 200 and 400mg/kg were evaluated using carrageenan-
induced paw edema method. The inflammation was readily produced in the form of 
edema with the help of irritant such as carrageenan. Carrageenan is a sulphated 
polysaccharide obtained from sea weed (Rhodophyceae) and when injected cause the 
release of prostaglandins by the way it produces inflammation and edema. 
REQUIREMENTS: 
Animal                        : Albino rat (180-200 g) 
Drugs and chemicals   : Carrageenan (1%w/v), Diclofenac sodium (standard), 
Carboxy methyl cellulose (1%w/v), 
Digital plethysmo meter. U G O Basile (Italy) 
Test compounds       :   siddha preparation  kandu parangi chooranam   
METHOD: 
Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1) The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the siddha formulation kandu 
parangi chooranam test Compounds dissolved with 2 ml sterile water given through 
orally 30 min before the carrageenan treatment. The paw volumes of the test 
compounds, standard and control groups were measured at 60,240,360 minutes of 
carrageenan treatment with the help of Digital plethysmometer (Ugo basile, Italy). 
Mean increase in paw volume was measured and the percentage of inhibition was 
calculated. 
  
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 Where, Vt-mean increase 
in paw volume in rats treated with test compounds, Vc-mean increase in paw volume 
in control group of rats. 
TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.35±0.82 - 
Group II  Std 
10mg/kg 
I.P.Diclofenac 
sodium 
1.75±0.60 67.50%*a 
Group III 
   siddha preparation  
kandu parangi 
chooranam 
200mg/kg.Orally. 2.15±0.50 60.64%*a 
Group IV 
  siddha preparation  
kandu parangi 
chooranam 
400mg/kg.Orally.  1.94±0.52 63.75%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s 
multiple range tests, to determine the significance of the difference between the 
control group and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
 
 Results 
Anti- inflammatory activity 
Both doses of  siddha preparation  kandu parangi chooranam   at 200mg/kg and 
400mg/kg were tested for their Anti- inflammatory activity by using carrageenan 
Induced rat paw edema method and the results are tabulated in table no 1.  The results 
reveals that   both doses of siddha preparation kandu parangi chooranam at 200mg/kg 
and 400mg/kg doses possesses significant Anti- inflammatory activity when 
compared to control group at p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ANTIHISTAMINIC AND ANTIANAPHYLACTIC ACTIVITY OF SIDDHA 
FORMULATION OF KANDUPARANGI CHOORANAM 
INTRODUCTION 
Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent years 
despite an improvement in the general health of the population.[1] Allergic diseases 
are responsible for significant morbidity and have severe economic impact.[2] 
Various epidemiological studies have identified the causes for an increase in the 
prevalence of upper and lower respiratory tract allergic diseases. Some of the 
postulated reasons are increasing environmental pollution [3] and increased 
predisposition of individuals producing excessive IgE through a major change in the 
gene pool, changing lifestyles, and an increasing awareness of the disorders.[4] 
Intensive research during the last several decades has highlighted the role of 
lymphocytes, immunoglobulins, mast cells, and various autacoids in the 
etiopathogenesis of allergic conditions. Inspite of the voluminous literature on the 
subject, the treatment of allergic diseases continues to be far from satisfactory. The 
available treatment options for upper and lower respiratory tract allergic diseases have 
major limitations owing to low efficacy, associated adverse events, and compliance 
issues.[5]  
AYUSH, an Indian system of medicine, has described several drugs from 
indigenous plant sources for use in the treatment of bronchial asthma and allergic 
disorders. In the present study, the effects of Siddha formulation of kandu parangi 
chooranam were studied on the active anaphylaxis and mast cell stabilization in rats, 
and histamine-induced bronchospasm in guinea pigs.  
MATERIALS AND METHODS 
ANIMALS 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either sex 
housed in standard conditions (temperature22 ± 2° C, relative humidity 60 ± 5% and 
12 h light/dark cycle) were used. They were fed with standard pellet diet and water ad 
libitum. ThInstitutional Animal Ethics Committee approved the experimental 
 protocol. Histamine and horse serum were procured from Sigma Chemicals and 
toluidine blue from Loba-Chemie, Mumbai. Elisa kit for IgE was supplied by Orion 
diagnostics, Espoc, Finland. All other chemicals and reagents were procured from Hi-
Media Laboratories limited, Mumbai. 
MAST CELL STABILIZING ACTIVITY 
TREATMENT PROTOCOL 
Twenty-four rats were divided into four groups of six animals in each group.  
Group I       served as control and received vehicle (water). 
Group II     (sensitized control group) 
GroupIII     served as the treatment control, which was treated with kandu parangi 
 chooranam at a dose of 200mg/kg body weight, in oral route. 
Group IV    served as the treatment control, which was treated with kandu parangi 
 chooranam  at a dose of 400 mg/kg body weight, in oral route. 
In group11 to group 1V were sensitized by injecting 0.5 ml of horse serum 
subcutaneously along with 0.5 ml of triple antigen containing 20,000 million 
Bordetella pertussis organisms (Serum Institute of India Ltd.,Pune), Once a day for 14 
days.  
On day 14, the rats were sacrificed 2 h after the treatment and the intestinal 
mesentry was taken out for the study on mast cells. Mesentries along with intestinal 
pieces were excised and kept in Ringer Locke solution (NaCl 154, KCl 5.6, CaCl2 
2.2, NaHCO3 6.0, glucose 5.55 mM/L of distilled water) at 37oC. The mesenteric 
pieces were challenged with 5% horse serum for 10 min after which the mast cells 
were stained with 1.0% toluidine blue and examined microscopically for the number 
of intact and degranulated mast cells.[6] 
HISTAMINE-INDUCED BRONCHOSPASM IN GUINEA PIGS 
Bronchospasm was induced in guinea pigs by exposing them to 1% histamine 
aerosol under constant pressure (1 kg/cm2) in an aerosol chamber (24 × 14 × 24 cm) 
made of perplex 
 
 Glass,of the three groups of six animals each. 
Group I served as control. 
GroupII     served as the treatment control, which was treated with kandu parangi 
 chooranam  at a dose of 200 mg/kg body weight, in oral route. 
Group III    served as the treatment control, which was treated with kandu parangi 
 chooranam at a dose of 400 mg/kg body weight, in oral route. 
The animals were exposed to 1% histamine aerosol under constant pressure (1 
kg/cm2) in an aerosol chamber on day 0 without any treatment. The end 
point,preconvulsive dyspnea (PCD) was determined from the time of aerosol 
exposure to the onset of dyspnea leading to the appearance of convulsions.[7] As soon 
as PCD commenced, the animals were removed from the chamber and exposed to 
fresh air. This PCD was taken as day 0 value. On days 1 and 5, 
2 h after the administration of the drug, the time for the onset of PCD was 
recorded as on day 0. 
STATISTICAL ANALYSIS 
The results of various studies were expressed as mean ± SEM and analyzed 
statistically using one-way ANOVA, followed by Newmann keul’s multiple range 
tests. P<0.05 was considered statistically significant.The analysis was performed 
using Graphpad Prism software package (Version 4.0). 
RESULTS 
Mast cell stabilizing potential of kandu parangi chooranam Antigen challenge 
resulted in significant degranulation of the mesentric mast cells. Pretreatment of 
sensitized animals with kandu parangi chooranam at a dose of 200mg/kg and 
400mg/kg, p.o., for 2 weeks resulted in a significant reduction in the number of 
disrupted mast cells (P <0.001) when challenged with horse serum.  
 
 
 
 EFFECT ON HISTAMINE-INDUCED BRONCHOSPASM 
kandu parangi chooranam at a dose of 200mg/kg and 400mg/kg p.o., 
significantly prolonged the latent period of PCD (P <0.001) as compared to control, 
following exposure to histamine aerosols on day 5 [Table no. 2]. 
DISCUSSION 
Experimental animal model of asthma is characterized by allergen-induced 
immediate airway constriction and late airway reactivity to a pharmacological 
vasoconstrictor such as histamine and leukotrienes. Histamine is a central mediator in 
the pathogenesis of allergic and inflammatory disorders. In the present study, kandu 
parangi chooranam prolonged the latent period of PCD in guinea pigs following 
histamine aerosol. This may be suggestive of an antihistaminic activity following 
treatment with kandu parangi chooranam. 
Antigen challenge, in sensitized animals, results in the degranulation of mast 
cells, which is an important feature of anaphylaxis. In the present study, kandu 
parangi chooranam showed marked protection against the mast cell degranulation 
following antigen challenge in sensitized animals. Mast cell stabilizing activity of 
kandu parangi chooranam may be attributed to the presence of active constituents 
which are known for their mast cell stabilizing potential against antigen–antibody 
reaction and/or due to the suppression of IgE antibody production, which is 
responsible for degranulation mast cells.[8]  
This antianaphylactic and antihistaminic effect may be caused by the 
stabilization of the mast cell membrane, suppression of IgE, and inhibition of 
pathological effects induced by the release of inflammatory mediators in kandu 
parangi chooranam treated animals. All the above findings lend credence to the 
beneficial use of kandu parangi chooranam  in the treatment of asthma and related 
conditions. 
However, further studies with other experimental models, especially to 
explore the role of cytokines are warranted to substantiate the antiasthmatic and 
antiallergic activity of kandu parangi chooranam. 
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 TABLE NO:1 EFFECT OF  KANDU PARANGI CHOORANAM ON 
MAST CELL STABILIZATION IN SENSITIZED RATS 
 
 
 Values are expressed as Mean±S.E.M 
       *a significantly different from sensitized control at p<0.01 
 
 
 
 
 
 
 
 
 
 
 
 
GROUPS                      MAST CELLS 
INTACT DISRUPTED 
NORMAL CONTROL 84.22±3.45 14.95±0.80 
SENSITIZED RATS 12.60±0.92 89.22±2.50 
kandu parangi chooranam 
200mg/kg 
66.22±2.72*a 36.50±1.35*a 
kandu parangi chooranam 
400mg/kg 
64.35±2.52*a 34.45±1.28*a 
 ANTIMICROBIAL STUDIES 
AIM 
 To study the Anti-microbial action of KANDUPAARANGI 
CHOORANAM against Steptococcus Pneumoniae & Staphylococcus 
Aureus  
MEDIUM 
COMPONENTS OF MEDIUM 
1. Beef extract  - 300gms/lit 
2. Agar   - 17gms/lit 
3. Starch   - 1.5gms/lit 
4. Casein Hydroxylate - 17.5gms/lit 
5. Distilled water - 1000ml 
6. PH   - 7.6 
PROCEDURE 
 The media was prepared from the components and poured and dried on 
a petri dish. The organism was streaked on the medium and the test drug (1gm 
drug in 10ml water) was placed on the medium. This is incubated at 37C for 
one over night and observed for night and observed for the susceptibility shown 
up clearance around the drug. 
RESULT: 
  The test drug KANDUPAARANGI CHOORANAM was  
Moderately sensitive against  Steptococcus Pneumoniae & Staphylococcus 
Aureus  
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
                                              PALAYAMKOTTAI 
       PG. DEPT. OF KUZHANTHAI MARUTHUVAM 
    CONSENT FORM 
___________________________________________________
_____ 
 An open clinical study to evaluate the safety and efficacy of Siddha 
sasthric formulation“KANDUPAARANGI CHOORANAM AND 
AKIRKATTAI THAILAM”for the management of “NEER PEENISAM”
              
                                       CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the 
terms readily understood by the parent. 
Date ……………….     
 Signature………….. 
place ……………….       Name 
……………… 
CONSENT OF INFORMANT 
 I have been informed to my satisfaction, by the attending physician, 
the purpose of the clinical trial, and the nature of drug treatment and 
follow-up including the laboratory investigations to be performed to 
monitor and safeguard my Son / Daughter body functions. 
 I am aware of my right to opt out of the trial at any time during the 
course of the trial without having to give the reasons for doing so. 
 I am, exercising  my free power of choice; hereby give my 
consent to be included as a subject in the clinical trial 
of“KANDUPAARANGI CHOORANAM AND AKIRKATTAI 
THAILAM”for the treatment of  “NEER PEENISAM” 
Date      Informant Signature……….. 
Place:     Informant  Name: …………. 
Signature of Witness    Patient Name:………………. 
      Relationship:………………… 
 ANNEXURE – IV 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
BRANCH IV – KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI - 627 002. 
CASE SHEET PROFORMA-“NEER PEENISAM” 
Name of the Medical unit:    Nationality: 
I.P.No.  :     Religion:  
Bed. No. :      Date of Admission: 
Name :      Date of Discharge: 
Age/Sex:      Duration of treatment :
  
Occupation(Parents):    Diagnosis: 
Income(Parents):     Medical Officer: 
Informant: 
Address:  
Complaints and duration  : 
History of present illness  : 
History of past illness  : 
Antenatal History   : 
Birth and Neonatal History  : 
 Dietetic and Nutritional History : 
Developmental History  : 
Family History   : 
Social History    : 
Immunization History  : 
General Examination  
1. Consciousness  : 
2. Decubitus  : 
3. Anemia  : 
4. Jaundice  :  
5. Cyanosis  : 
6. Clubbing  : 
7. Pedal oedema  : 
8. Lymphadenopathy  : 
9. Nourishment  : 
10. Skin changes  : 
Vital Signs 
1. Pulse 
      -Rate  : 
      -Rhythm  : 
      -Volume  : 
      -Character  : 
    2.  Blood Pressure (B.P).  : 
      3. Respiratory Rate (R.R.)  : 
      4. Temperature  : 
        
ANTHROPOMETRY 
1. Wt – Weight  : 
2. Ht  -  Height  : 
3. Mid arm circumference  : 
4. Head circumference  : 
5. Chest  : 
6. Skin fold thickness  : 
Siddha Systems – Clinical Examination: 
Poripulangal 
           Mei  : 
           Vai  : 
           Khan  : 
           Mookku  : 
           Sevi  : 
Kanmendriyam – Kanmavidayam 
           Kai  : 
           Kaal  : 
           Vaai  : 
           Eruvaai  : 
           Karuvaai  : 
 Nilam 
           Kurinchi  : 
           Mullai  : 
           Marutham  : 
           Neithal  : 
           Palai  : 
Paruva Kaalam 
           Kaar  : 
           Koothir  : 
           Munpani  : 
           Pinpani    : 
           Elavenil   : 
           Muthuvenil  : 
Udal Kattugal 
             Saaram  : 
             Senneer  : 
             Oon  : 
             Kozhuppu  : 
             Enbu  : 
             Moolai  : 
             Sukkilam/Suronitham  : 
 
 Envagai Thervugal 
Naadi  : 
Sparisam  : 
Naa  : 
Niram  : 
Mozhi  : 
Vizhi  : 
Malam  : 
Moothiram  : 
   Vatham 
               Piranan  : 
              Abaanan  : 
              Uthaanan  : 
              Viyaanan  : 
              Samaanan  : 
              Naagan  : 
              Koorman  : 
              Kirugaran  : 
              Devathathan  : 
              Dhananjeyan  : 
 Pitham 
                Analam  : 
              Ranjagam  : 
              Sathagam  : 
              Alosagam  : 
              Pirasagam  : 
Kabam 
              Avalambagam  : 
              Kilethagam  : 
              Pothagam  : 
              Tharpagam  : 
              Santhigam  : 
Neerkuri 
              Niram  : 
              Manam  : 
              Nurai  : 
              Edai  : 
              Enjal  : 
 
 Neikuri 
Malakuri 
              Nirami  : 
              Nurai  : 
              Elagal  : 
              Erugal  : 
Modern Aspects 
Systemic examination 
Cardiovascular systems: 
1. Inspection: 
2. Palpation: 
3. Percussion: 
4. Auscultation: 
Examination of other systems 
Respiratory systems: 
Abdomen: 
Central nervous systems: 
Excretory systems: 
 
Lab Investigations 
1. Blood 
TC : 
DC : 
Hb : 
ESR : 
PCV : 
MCV : 
 MCH : 
MCHC : 
Total RBC count : 
Peripheral blood smear : 
 
2. Urine 
Albumin : 
Sugar : 
Deposits : 
Bile Salt : 
Bile pigments : 
3. Motion 
Ova : 
Cyst : 
Occult blood : 
X-ray : PNS : 
X-ray Chest : 
 
DIFFERNTIAL DIAGNOSIS : 
PROGNOSIS   : 
MARUTHUVAMURAI  : 
ADVICE   : 
DAILY PROGRESS   : 
 
Date 
 
Symptoms Medicine 
   
   
 
 
 
 GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
BRANCH IV – KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI - 627 002. 
ADMISSION – DISCHARGE SHEET 
Name of the medical unit :  Nationality: 
I.P.No                                :  Religion: 
Bed No                              :  Informant: 
Name                                 :  Date of Admission: 
Age/Sex                             :  Date of Discharge: 
Occupation(parents)          :  No. of days treated : 
Income(parents)                 :  Diagnosis   
S.No Clinical Features During 
admission 
During 
discharge 
    
    
    
    
    
    
    
    
Place: 
Date:  Signature of the Medical Officer, 
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